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ABSTRACT 
 
Equine Herpesvirus type 1 (EHV-1) is a worldwide threat to the health of horses. It can cause 
mild respiratory disease, abortions and deaths of newborn foals as well as a potentially fatal 
neurologic disorder known as Equine Herpesvirus Myeloencephalopathy (EHM). The virus is 
maintained in populations by stress-induced periodic reactivation of virus in long-term latently 
infected horses and transmission of the reactivated virus to susceptible individuals. In horses, 
peripheral blood leukocytes (PBLs) are thought to be an important site for EHV-1 latent 
genomes. Since the Unfolded Protein Response (UPR) is a cellular response to a variety of 
stressors that has been linked to reactivation of herpes simplex virus in humans, a virus closely 
related to EHV-1, I tested the hypothesis that latent EHV-1 relies on the UPR as a pluripotent 
stress sensor and uses it to reactivate lytic gene expression.  
Since little work has been done in defining the UPR in horses, I first successfully developed a 
quantitative real-time polymerase chain reaction (RT-qPCR) assay to detect and quantitate 
transcripts for selected UPR genes in equine dermal (E.Derm) cells and PBLs. Activation of the 
UPR was achieved in both cell types using thapsigargin and a difference in gene expression after 
activation of the UPR in two equine cell types was found. A nested PCR assay to detect and 
distinguish latent EHV-1 and EHV-4 was evaluated and the sensitivity of the technique to detect 
EHV-1 was determined. I discovered that the nested PCR technique was not sensitive enough to 
detect the estimated one latent viral genome in 50,000 PBLs.  
Lytic EHV-1 infection was characterized by single step growth curve in E.Derm cells and 
consistent detection of temporal EHV-1 gene expression by RT-qPCR was achieved. The 
relationship between EHV-1 gene expression and UPR gene expression during lytic infection 
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was investigated. While EHV-1 infection had no effect on UPR gene expression, activation of 
the UPR appeared to decrease the expression of EHV-1 genes temporarily and reversibly during 
the first 4 h after infection. Finally, detection of EHV-1 in PBLs from horses presumed to be 
latently infected by co-cultivation with E. Derm cells permissive to EHV-1 infection was 
attempted. To detect viral DNA, PBLs were stimulated with thapsigargin or interleukin 2 (IL-2) 
which was previously reported to induce reactivation of latent EHV-1. I was not able to 
reproduce previously published experiments of reactivation in vitro of latent EHV-1 by 
stimulation with IL-2, and virus reactivation did not occur after stimulation of PBLs with 
thapsigargin. 
In summary, a RT-qPCR assay to measure the expression of equine UPR genes was developed 
and activation of the UPR by treatment of E.Derm cells and PBLs with thapsigargin was 
successfully achieved. A difference in gene expression after activation of the UPR in two equine 
cell types was found. In contrast to what has been reported for other alphaherpesviruses, there 
appears to be no, or only little, interaction between the UPR and EHV-1 during viral infection. 
Detection of latent EHV-1 genomes in PBLs was not achieved by using a nested PCR, as this 
technique was not sensitive enough to detect the estimated one latent viral genome in 50,000 
PBLs. Finally, latent EHV-1 was not detected in presumed latently infected PBLs or reactivated 
by triggering the UPR in equine PBLs.    
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1 LITERATURE REVIEW, HYPOTHESIS AND OBJECTIVES 
1.1 General introduction 
Equine herpesvirus type 1 (EHV-1) is present in herds of horses around the world 
(Matumoto, Ishizaki et al. 1965) and can induce respiratory disease, abortions, mortality of 
newborn foals and a neurological disease (Charltons, Mitchell et al. 1976) that can be fatal, 
known as equine herpes virus myeloencephalopathy or EHM (Allen 2004). Dimock and Edwards 
(1936) described outbreaks of abortion in mares as epizootic or virus abortion. The lesions they 
described in aborted fetuses were consistent with EHV-1 induced lesions (Dimock and Edwards 
1936). The virus was first identified as the cause of abortion in mares and it was thought to be a 
manifestation of equine influenza. Later, it was determined to be a different agent than the 
influenza A virus (Doll and Kintner 1954) and several names were assigned to it until equine 
herpesvirus type 1 was officially proposed by Plummer and Waterson in 1963 (Plummer and 
Waterson 1963).  
There are some characteristics of EHV-1 that allow it to persist and circulate within the 
equine population. Excretion and entry of the virus through the respiratory tract facilitates 
transmission between animals. One particular aspect of herpesviral infection is the establishment 
of latency, a process by which the virus infects a particular type of cells and remains in a non-
replicative state, hiding from the immune system of the host for an undetermined period of time. 
Under appropriate conditions, latent virus can revert to an infective state in a process called 
reactivation from latency (Roizman and Baines 1991). The ability of the herpesviruses to 
establish latency and to reactivate from this latent state makes it a challenge to control 
transmission because, usually, clinical signs are not easily detected during the reactivation 
process. Latent virus carrier animals reactivating virus can be the source of infection to other 
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animals, including re-infection of latently infected horses. Diagnostic techniques that are able to 
detect latently infected animals are needed and research in this area has increased in recent years 
(Allen 2006). The economic impact of EHV-1 infection in the equine industry is apparent by the 
restriction on the transport of horses when outbreaks are detected in an area. In addition, the 
potentially high number of abortions during EHV-1 outbreaks (abortion storms) and the delay in 
training of young horses affected with respiratory disease pose another threat to the success of 
the equine industry. The incidence of EHM during outbreaks can range from 10% to more than 
30% (Goehring, van Winden et al. 2006). Mortality rates of around 40% raise concerns in the 
equine industry (Allen 2004; Lunn, Davis-Poynter et al. 2009). 
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1.2 Herpesviridae family 
Viruses within the family Herpesviridae were originally classified based on structures 
identified by electron microscopy. Now that nucleotide sequencing is more accessible, new 
taxonomic classifications have been proposed to reorganize this diverse group of over 200 
viruses that have been identified in mammals, birds and reptiles. The classic identification of 
herpesviridae has been divided into subfamilies (alpha, beta, and gamma) and each subfamily is 
subdivided into different genera (Flint, Enquist et al. 2004; Roizman 2007). Table 1.1 shows 
examples of herpesviruses representing each genus. The following are biological characteristics 
shared among the family members:  
1. Variety of enzymes: Even though there is variation between different herpesviruses, all 
possess a considerable array of enzymes involved in protein processing, nucleic acid 
metabolism and synthesis. 
2. Nuclear replication: While the final processing of the mature virion occurs in the cytoplasm, 
the synthesis of the viral genome and the assembly of the nucleocapsid take place in the 
nucleus. 
3. Cellular damage: Damage of the infected cell is inevitable for the egress of the infectious 
virions from the cell. 
4. Latency: The viruses have the ability to remain latent in the host, where no detectable 
infective progeny is produced until reactivation events occur.  Also, the genome adopts a 
circular form in the latently infected cells and only selected latency associated viral genes are 
expressed.  
While members of the family Herpesviridae share a considerable number of 
characteristics, the biological properties that differ among its members include the cell type 
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where the virus establishes latency, the ability to infect one or more hosts, the rate to infect and 
destroy the infected cells, and the clinical manifestations of infection (Roizman, Desrosiers et al. 
1992; Alder, Shen et al. 2005; Roizman 2007). 
1.2.1 Alphaherpesvirinae subfamily 
EHV-1 is a member of the Alphaherpesvirinae subfamily of the Herpesviridae family. 
EHV-1 is included in this subfamily as a member of the genus Varicellovirus. Within this genus 
there are several viruses that can cause disease to animals and humans: Varicella-zoster virus 
(HHV-3 or VZV), Bovine herpesvirus 1 and 5 (BoHV-1 and BoHV-5), Canine herpesvirus 1 
(CaHV-1), Equine herpesvirus 3, 4, 8 and 9 (EHV-3, 4, 8 and 9), Felid herpesvirus 1 (FeHV-1) 
and Suid herpesvirus 1 or pseudorabies virus (SuHV-1 or PRV) are some examples. The 
alphaherpesviruses are characterized by a variable host range, the ability to multiply quickly, to 
spread rapidly in culture, to produce lysis in infected cells (Roizman and Baines 1991) and to 
establish latency in long lived differentiated cells, primarily in sensory ganglia (Roizman 2007). 
In addition to establishing latency in sensory ganglia, BoHV-1, EHV-1 and PRV have been 
proposed to establish latency in lymphoid tissues, although the evidence for this is inconclusive. 
EHV-1 has further been described to establish latency in peripheral blood leukocytes (Gleeson 
and Coggins 1980; Chesters, Allsop et al. 1997) while latent genomes of neither BoHV-1 nor 
PRV have been detected in PBLs (Balasch, Pujols et al. 1998; Winkler, Doster et al. 2000).  
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Table 1.1 Herpesviridae subfamilies and genus examples with name and abbreviations. 
Main characteristics of each subfamily are detailed.  
Subfamily Genus Common names 
(abbreviations) 
Characteristics of 
subfamily 
Alphaherpesvirinae Simplexvirus 
 
 
Varicellovirus 
 
 
 
 
 
 
 
 
 
Iltovirus (avian) 
 
 
Mardivirus (avian) 
Herpes simplex virus (HSV-
1) 
 
Varicella-zoster virus (VZV 
or HHV-3) 
Equine herpes virus 1 (EHV-
1) 
Bovine herpes virus 1 
(BoHV-1) 
Pseudorabies virus (PRV or 
SuHV-1) 
 
 
Infectious laryngo-
tracheitisvirus (GaHV-1) 
 
Marek disease herpes virus 
(GaHV-2) 
Variable host range, 
rapid spread in culture, 
short reproductive 
cycle, destruction of 
infected cells and 
establishment of latency 
primarily (but not 
exclusively) in sensory 
ganglia.  
Betaherpesvirinae Cytomegalovirus 
 
Muramegalovirus 
 
Roseolovirus 
 
Proboscivirus 
Human cytomegalovirus 
(HCMV) 
Murine cytomegalovirus 
(MuCMV) 
Human herpesvirus 6 
(HHV-6) 
Endotheliotropic elephant 
herpesvirus 1 (ElHV-1) 
Restricted host range, 
long reproductive cycle, 
slow progression in 
culture 
Gammaherpesvirus Lymphacryptovirus 
 
 
Rhadinovirus 
Epstein-Barr virus (EBV or 
HHV-4) 
 
Kaposi sarcoma associated 
herpesvirus (KSAH or HHV-
8) 
 
Infection specific to 
either T or B 
lymphocytes. 
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1.3 Equine Herpesvirus type 1 
1.3.1 EHV-1 virion properties and genome structure 
The EHV-1 genome is a 150,000 bp linear double stranded DNA packed in torus shape 
forming the core, which is surrounded by an icosahedral capsid. The capsid consists of 162 
capsomeres of which 150 are hexons and 12 are pentons and it has an approximate diameter of 
100 nm. Core and capsid form the nucleocapsid, which is enclosed by an amorphous and 
asymmetrical protein-containing layer, known as the tegument. The envelope is the outer 
lipoprotein layer composed of cellular host membrane and embedded viral glycoproteins 
(Roizman and Baines 1991; Maclachlan and Dubovi 2010).  
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Figure 1.1 EHV-1 genome. The linear disposition of the viral genome consisting of a unique 
long region (UL, 112,870 bp) bordered by 32 bp of internal and terminal repeated sequences (IRL 
and TRL, respectively) and a unique short region (US, 11,861 bp) bordered by 12,777 bp of 
internal and terminal repeated sequences (IRS and TRS, respectively). The US can be present in 
two directions as a result of inversion in the orientation of the TRS and the IRS with respect to the 
fixed orientation of the UL, resulting in two different isomers of the viral genome during virus 
replication. 
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The viral genome (Figure 1.1) has a base composition of 56.7 % G+C (Telford, Watson 
et al. 1992) and consists of a long unique region (UL) of 112,870 bp covalently linked to a short 
unique region (US) of 11,861 bp. Both, the UL and the US regions are bordered by internal and 
terminal inverted repeated sequences: a small inverted repeated sequence of 32 bp (TRL; IRL) 
bordering the UL, and a large inverted repeated sequence of 12,777 bp (TRS; IRS) bordering the 
US (Yalamanchili and O'Callaghan 1990; Mahy and Van Regenmortel 2008; O'Callaghan and 
Osterrieder 2008). The US can be present in two directions as a result of inversion in the 
orientation of the TRS and the IRS with respect to the fixed orientation of the UL, resulting in two 
different isomers of the viral genome during virus replication (Allen 2004). The viral genome 
comprises 80 open reading frames (ORFs) including four duplicated ORFs present in the TRS 
and the IRS. Within the UL region, 63 ORFs are organized identically to other alphaherpesviruses 
(EHV-4, HSV and VZV); however, a number of genes within the US region and its IRS are 
organized differently. Unique to EHV-1 and EHV-4 is a group of five genes not found in any 
other alphaherpesviruses. These five distinctive genes of unknown function are presumed to be 
the genes involved in host specificity (Allen 2004; O'Callaghan and Osterrieder 2008).  
1.3.2 EHV-1 proteins 
The virus encodes 76 genes that can be differentiated into the immediate early (IE) or α, 
early (E) or β and late (L) or γ categories based on the order requirements for their expression. 
EHV-1 possesses only one IE gene and several transcripts have been recognized for the E and 
the L categories: approximately 45 E transcripts and about 29 L (O'Callaghan and Osterrieder 
2008). Efficient expression of the IE gene (ORF64, IRS) requires the virion-associated 
transactivator, E-VP16 (ORF12) (Elliott 1994; Purewal, Allsopp et al. 1994), and the IE product 
trans-activates other viral genes and is also able to regulate itself (Kim, Dai et al. 2012). Four E 
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gene products act as regulatory proteins: EICP22 (ORF67) is a trans-activator synergistic with 
the IE protein (Kim, Holden et al. 1997); EICP27 (ORF5) stimulates transcription of E and L 
genes (Albrecht, Kim et al. 2004); EICP0 has an antagonist effect on the IE protein while it is a 
potent transactivator of the other two classes of temporal genes; and IR2 (ORF64, TRS) 
negatively regulates gene expression. Viral genes encoding proteins involved in virus replication, 
such as the DNA polymerase gene (ORF30), the thymidine kinase gene (ORF38) and the 
ribonucleotide reductase gene (ORFs 20, 21) are also found within the early category (Telford, 
Watson et al. 1992; Allen 2004; O'Callaghan and Osterrieder 2008; Dubovi and Maclachlan 
2011). The late genes encode structural proteins. Six genes code for proteins that form part of the 
capsid (ORFs 22, 25, 35, 35.5, 42 and 43), twelve genes code for proteins associated with the 
tegument (ORFs 11, 12, 13, 14, 15, 23, 24, 40, 46, 49, 51 and 76) and twelve genes code for 
glycoproteins present in the envelope (Table 1.2). These glycoproteins can be classified further 
as essential for virus replication in vitro or not essential for virus replication in vitro (Table 1.2). 
The main functions of these glycoproteins are related to viral binding, penetration, assembly, 
egress and spreading from cell to cell. The late gene 12 (ORF 12) codes for the tegument protein 
E-VP16/ETIF, a homologue to the HSV-1 VP16/α-TIF (α trans-inducing factor). Although the 
main regulatory function of EHV-1 E-VP16 is the transactivation of the IE promoter, it is not 
essential for viral gene expression and viral DNA replication (Von Einem, Schumacher et al. 
2006). E-VP16 also plays a key role in secondary viral envelopment and it contributes to virion 
structure by its presence on the viral tegument (Lewis, Thompson et al. 1993; Von Einem, 
Schumacher et al. 2006; Sellon and Long 2007; O'Callaghan and Osterrieder 2008). 
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 Table 1.2 EHV-1 glycoproteins: name, ORF, function and classification 
Name ORF Function Classification
1
 
gK 
gN 
gC 
gB 
gH 
gM 
gL 
gG 
gp2 
gD 
gI 
gE 
6 
10 
16 
33 
39 
52 
62 
70 
71 
72 
73 
74 
Viral egress and spread from cell to cell 
Virus assembly; necessary for maturation of gM 
Viral egress and viral attachment to cells 
Viral binding, penetration and spread from cell to cell 
Crucial for plaque formation in vitro/undetermined in vivo
2
  
Viral binding, penetration and spread from cell to cell 
Undetermined  
Immunomodulatory 
3
 
Viral binding, penetration and spread from cell to cell 
Viral binding, penetration and spread from cell to cell 
Viral spread from cell to cell 
Viral spread from cell to cell 
Es 
NEs 
NEs 
Es 
Es 
NEs 
Es 
NEs 
NEs 
Es 
NEs 
NEs 
    
                                                 
1
 Es: essential for viral replication in vitro; NEs: not essential for viral replication in vitro 
2
 Azab, Zajic et al. 2012 
3
 Thormann, Van de Walle et al. 2012 
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1.3.3 EHV-1 gene expression during lytic infection 
As with most herpesviruses, EHV-1 gene expression during lytic infection is arranged in 
a rigorously regulated temporal mode. Upon entry of the viral nucleocapsid into the infected cell, 
tegument proteins are released in the cytoplasm and the viral DNA, accompanied by E-VP16, 
reaches the cellular nucleus. (Figure 1.2) The IE gene expression is strongly activated by the E-
VP16 protein and the IE mRNA is transcribed by the cellular RNA polymerase II; the E genes 
require IE protein activation to be transcribed and translated into E proteins. The IE protein and 
the E proteins suppress the translation of more IE mRNA while inducing replication of viral 
DNA and transcription of L genes. The translated L proteins downregulate the expression of the 
IE and the E genes (Gray, Baumann et al. 1987; Lewis, Thompson et al. 1993; O'Callaghan and 
Osterrieder 2008). 
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Figure 1.2 EHV-1 gene expression during lytic infection. The IE gene transcription is 
activated by E-VP16. The IE protein activates transcription of E and L genes. The E proteins 
activate transcription of L genes while suppressing expression of the IE gene. The L proteins 
suppress expression of E and IE genes. The IE gene auto-regulates its own expression. Dashed 
arrows represent suppression activity; solid arrows represent stimulation. Adapted from (Sellon 
and Long 2007) 
 
 
 
 
 
 
 
 
E-VP16 
IE genes E genes L genes 
 13 
 
1.3.4 EHV-1 viral cycle and propagation 
EHV-1 virions attach to the respiratory epithelium through the envelope glycoproteins 
and enter the cells. The equine major histocompatibility complex (MHC) class I molecules have 
been described as a gD receptor for viral entry (Sasaki, Hasebe et al. 2011). An initial replication 
at the point of entry takes place. This lytic cycle takes approximately 20 h and is conducted in 
the following order: 1) attachment to the host cell membrane 2) membrane fusion and 
penetration into the cell or entry through endocytic pathways (Hasebe, Sasaki et al. 2009) 3) 
translocation of viral DNA to the nucleus 4) egress of assembled nucleocapsid from the nucleus 
5) envelopment of the virions 6) offspring virions released causing cell lysis. The initial 
replication enables the virus to infect neighbouring epithelial cells and also dermal cells, 
neuronal axons (from where it will access the trigeminal ganglion around two days post 
infection) (Slater, Borchers et al. 1994), dendritic cells and leukocytes in the lamina propria. 
These infected leukocytes transport the virus via the lymphatic circulation to the draining lymph 
nodes where a second viral multiplication takes place, which allows the virus to gain entry to the 
blood circulation in a process called leukocyte-associated viremia. The virus then establishes a 
non-productive infection of leukocytes, the majority of which do not express viral antigens on 
the cell surface and, therefore, are not recognized by the immune system as infected. The 
infected leukocytes reach distant organs where the virus can infect the vascular endothelium and 
replicate, causing clinical signs such as abortion or neurological syndrome. (Gibson, Slater et al. 
1992) (Goehring, Hussey et al. 2011). 
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1.4  EHV-1 pathogenesis and clinical signs  
1.4.1 EHV-1 virulence 
Ab4 and V592 are two EHV-1 field strains that have been extensively studied. Ab4 was 
isolated in 1980 from a quadriplegic mare who had aborted during an outbreak of paresis in 
geldings and mares (Crowhurst, Dickinson et al. 1981). Ab4-like strains are characterized by a 
high virulence, high endothelial cell tropism, and high levels of viremia. The viremia levels 
remain elevated for extended periods of time in horses infected with Ab4-like strains. Ab4-like 
strains have been found in most EHM outbreaks (Goodman, Loregian et al. 2007). V592 was 
isolated from a fetus during an abortion storm in 1985 (Mumford, Rossdale et al. 1987). V592-
like strains are characterized by low virulence, reduced endothelial cell tropism, low levels of 
viremia of short duration and have been found to be involved in most non-neurological outbreaks 
(Goodman, Loregian et al. 2007). The difference in the virulence of Ab4 and V592 variants is 
attributable to a dimorphism in the sequence of gene 30 (ORF 30) that codes for the DNA 
polymerase. The dimorphism at nucleotide position 2254 causes a substitution of amino acids at 
position 752: asparagine (N) in V592 for aspartic acid (D) in Ab4. The N752 variant has been 
found in almost 98% of the outbreaks associated with abortions and close to 25% of the 
outbreaks associated with EHM, accounting for most of the viral genotypes that are circulating in 
horses (Allen and Breathnach 2006). This means that neither clinical presentation is exclusively 
caused by a particular variant (Nugent, Birch-Machin et al. 2006; Goodman, Loregian et al. 
2007). The infection with the D752 variants appear to show increased severity and number of 
lesions in the central nervous system (CNS) which could be attributed to the increased replicative 
capacity. This variant has been found to be more common in neurologic outbreaks (Allen and 
Breathnach 2006; Goodman, Loregian et al. 2007) 
 15 
 
1.4.2 EHV-1 transmission 
Respiratory secretions of infected animals shedding infective particles during lytic cycles 
of the virus, either from a primary infection or from reactivation episodes, are the main source of 
EHV-1. Fetal membranes or reproductive tract secretions immediately after abortion are also a 
source of highly infectious virus (Gibson, Slater et al. 1992); (Goehring, Hussey et al. 2011). 
One study, investigating the nasal shedding of EHV-1 by serially testing EHV-1 positive animals 
during an EHM outbreak, suggested that nasal shedding can take place for up to 9 days from the 
day the animal starts presenting with neurological signs (Burgess, Tokateloff et al. 2012). 
Perpetuation of EHV-1 in the population is due to reactivation from latency and continual 
introduction of susceptible animals. For example, latently infected mares that reactivate virus can 
infect foals before weaning, and transmission between foals then spreads the disease in the herd. 
Depending on the vaccination status, the age of the animals and the movement of horses in or out 
of the herd, the transmission of the disease could vary. In most cases, natural infection and 
reactivation episodes do not present with evident clinical signs (Edington, Bridges et al. 1985). 
Mild respiratory disease can occur but is usually not noticed by the caretaker of the animals 
(Allen 2004).  
1.4.3 Clinical signs of EHV-1 infection  
1.4.3.1 Respiratory disease 
The presentation of clinical signs of respiratory disease can vary in duration and severity 
depending on different factors: age of the animal, immune status and virulence of the virus 
strain. After experimental infection, the incubation period can range from one to ten days. 
During the first 24 h of infection, the virus replicates in epithelial cells of the upper respiratory 
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tract, generating erosions in the mucosa. The virus then reaches the lamina propria, infecting 
endothelial cells and leukocytes that travel to the draining lymph nodes (Gibson, Slater et al. 
1992) (Allen 2004). Fever usually begins and subsides within the first 24-48 hours post-infection 
(HPI). In many cases, the fever reappear a week after infection with enlargement of lymph 
nodes. The initial respiratory disease is in the upper respiratory tract and characterized by 
rhinopharyngitis and tracheobronchitis with the occasional presence of coughing. If the host has 
never encountered EHV-1 previously, the presentation of respiratory signs can be severe and 
secondary bacterial infections are common. In cases of uncomplicated viral respiratory 
infections, the nasal discharge is serous; however, it can change to mucopurulent with secondary 
infections. An uncomplicated upper respiratory tract infection with EHV-1 will typically resolve 
within three weeks (Allen 2004).  
1.4.3.2 Abortion and neonatal disease 
When initial infection with EHV-1 or reactivation from latency takes place during 
pregnancy, a late-term abortion without premonitory signs or delivery of a weak or stillborn term 
foal can occur (Reed and Toribio 2004). Most abortions occur in the last trimester of gestation 
while the fetus and placenta do not seem to be affected during the first and second trimester 
(Smith, Mumford et al. 1996). The virus can reach the pregnant uterus by leukocyte-associated 
viremia or by reactivation in-situ of latent virus (Bryans 1969; Gleeson and Coggins 1980; Allen 
2004). It affects primarily the small arteriolar branches in the glandular layer of the 
endometrium, predominantly at the site where highly vascularized chorionic villi 
(microcotyledons) extend into elaborate invaginations of the endometrium, causing vasculitis, 
ischemia and thrombosis. Depending on the severity and extent of these lesions, the infection can 
result in separation of the placenta, leading to asphyxia of the fetus and abortion. In most cases, 
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virus can be recovered from the aborted fetus showing that the virus crosses the fetal-placental 
barrier. Not all of the mechanisms of EHV-1 infection in the pregnant uterus are fully 
understood.  The highly virulent strains of EHV-1 have a high affinity for endothelial cells 
(Goehring, Hussey et al. 2011), which may explain the severity and widespread nature of the 
lesions in the endometrium.  However, this does not fully explain the pathogenesis of abortion 
because low virulence strains with lower affinity for endothelial cells should cause less severe 
inflammation, but can also cause abortion (Smith 1999; Allen 2004). In those cases where the 
virus does not cause abortion, foals are born with or rapidly develop acute respiratory disease, 
intractable diarrhea, pyrexia and lethargy that lead to death within a few days (Allen 2004). 
1.4.3.3  Equine herpesvirus myeloencephalopathy 
Viremia is a pre-requisite for the development of neurological signs as leukocyte-
associated viremia transports EHV-1 infected cells throughout the circulatory system, providing 
the virus an opportunity to reach endothelial cells in the CNS tissue (Goehring, van Maanen et al. 
2010). There is insufficient evidence to support the hypothesis for lytic EHV-1 infection of 
neurons. The magnitude of post-exposure viremia has been identified as a risk factor for  the 
development of neurological disease in experimental EHV-1 infection (Allen 2008), suggesting 
that endothelial exposure to high viral loads raises the risk of EHM (Allen 2008; Goehring, van 
Maanen et al. 2010; Wilsterman, Soboll-Hussey et al. 2011). Although not proven, it is suspected 
that sustained exposure to infected PBLs leads to higher rates of infection in the endothelial cells. 
The virus can be detected in endothelial cells in the CNS by immunofluorescence (Edington, 
Bridges et al. 1986). The pathogenesis of EHM includes vasculitis, thrombosis and ischemic 
necrosis of the affected tissue in the brain, in the spinal cord or in both sites, which may be 
accompanied by hemorrhage. Death of nervous tissue as a consequence of the endothelial 
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damage by EHV-1 infection causes myeloencephalopathy and generates the neurological signs 
(Reed and Toribio 2004). Endothelial cell infection by direct contact with EHV-1 infected 
leukocytes appears to be one way by which the virus evades the immune system (Goehring, 
Hussey et al. 2011). Conversely, it has been proposed that the horse’s immune response may 
exaggerate the virally induced vascular lesions, thereby intensifying the pathogenesis of EHV-1 
neurological syndrome (Allen 2004). The neurological signs are diverse and are correlated with 
the lesion location within the CNS and severity of the lesions. Generally, signs start between six 
and ten days after the initial infection. This initial infection may be associated with fever and 
respiratory signs (Edington, Bridges et al. 1986). Possible clinical signs are: edema in the limbs 
or abdomen, limb weakness, ataxia, proprioceptive deficits, stumbling, complete paralysis with 
subsequent recumbency, bladder atony followed by urine retention or incontinence, poor tail and 
anal tone and fecal incontinence or inability to pass feces. Urine scalding as a consequence of 
bladder paralysis, bladder rupture, colic and pneumonia are possible sequellae to CNS infection. 
Prognosis for recumbent animals is generally considered poor (Allen 2004).  
 
1.5  Latency and reactivation of alphaherpesviruses 
This section will cover latency and reactivation in alphaherpesviruses, with focus on 
HSV-1 as it has been the most studied virus of this subfamily.  
One of the most remarkable characteristics of herpesviruses is the ability after initial 
infection to remain latent within that host. Viral genomes can persist in infected cells without 
production of viral progeny and hidden from the host immune system. Two theories concerning 
the establishment of latency were proposed in the past: the “static theory” and the “dynamic 
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theory”. According to the static theory, there is a failure of the virus’ ability to express viral 
genes with the exception of the latency associated transcripts or LAT and, hence, there is no viral 
genome replication. Changes that have not yet been identified in the infected cell’s intracellular 
environment allow reactivation and viral replication. According to the dynamic theory, the host 
immune system is in control of viral replication, keeping it at a minimum. Reactivation is a 
consequence of a weakened immune system. Neither of these theories has proven correct 
although they have not been proven wrong. The molecular mechanisms of latency and 
reactivation have not yet been clarified completely (Stevens 1989; Preston 2008).  
The initial infection site for HSV-1 is the epithelium in mucosa, cornea and skin after 
direct contact, usually without viremia. For VZV, the route of infection is inhalation of infected 
respiratory tract secretions with the initial infection taking place in epithelial and immune cells 
followed by a cell-associated viremia and a secondary cell infection in the subdermis. Both 
viruses infect neurons by accessing the axons in the skin. However, HSV-1 infects neurons that 
innervate the site of the initial replication and establishes latency in neurons of the trigeminal 
ganglia while VZV, thanks to the cell-associated viremia, can infect and establish latency in 
sensory neurons and autonomic ganglia across the entire neuraxis (Kinchington, St Leger et al. 
2012). In contrast, EHV-1-induced leukocyte-associated viremia transports the virus to distant 
locations where it can infect more leukocytes or endothelial cells. There is no definitive or clear 
evidence that EHV-1 replicates in equine neurons (Allen 2004) and there is only anecdotal 
evidence showing infection of neurons in locations other than the trigeminal ganglia (Patel, 
Edington et al. 1982; Slater, Borchers et al. 1994).             
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1.5.1 Establishment and maintenance of alphaherpesvirus latency 
Different ideas about the mechanisms by which HSV-1 establishes latency in neurons 
have been proposed. One hypothesis, that could support the static theory of latency 
establishment, proposes that during the viral infection of neurons, the early viral cycle is 
interrupted due to a lack in the transport of the transactivator VP16 into the neuronal nucleus or 
due to a reduced interaction of VP16 with cellular factors such as HCF and Oct1 that start IE 
gene transcription (Lakin, Palmer et al. 1995; Kristie, Vogel et al. 1999; Kolb and Kristie 2008). 
Both scenarios suggest insufficient IE gene expression and repression of the lytic cycle in 
neurons; consequently there is no expression of viral proteins and the viral genome remains in 
the infected cell. Another hypothesis proposes that during the primary infection, the virus can 
either induce productive infection or latent infection, suggesting that productive infection is not a 
requirement for establishment of latency (Nicoll, Proença et al. 2012).  
The linear genome of all alphaherpesviruses adopts a circular conformation and is 
assembled into nucleosomes in latently infected cells (Roizman 2007). In the case of HSV-1 lytic 
infection, it has been shown that  viral proteins and LAT are expressed in less than 1% of 
infected neurons (Speck and Simmons 1992). It has also been proposed that the number of latent 
viral genomes in latently infected neurons could be related to the establishment, maintenance and 
reactivation of latency, as an enormous difference between the numbers of genomes in the 
infected neurons has been found (Sawtell 1997). How the virus genome can be present within 
cells in such variable numbers and how the cell can survive the initial infection without damage 
could be explained by the presence of CD8
+ 
T cells surrounding latently infected tissues. These 
immune cells can restrain the viral replication in a non-cytolytic fashion by recognising viral gB, 
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and inhibit viral gene expression at the last stage of the lytic cycle (Decman, Kinchington et al. 
2005).  
It is still not clear which mechanisms are more relevant to establishment of HSV-1 
latency, but there is a possibility that it requires expression of viral proteins and does not depend 
on a total inhibition of the viral gene expression (Roizman 2007; Nicoll, Proença et al. 2012). 
The only transcripts consistently detectable in some latently infected neurons are the LAT. These 
transcripts do not encode proteins (Stevens, Wagner et al. 1987; Wagner and Bloom 1997). The 
direct role of the LAT in the establishment of latency is controversial. In a mouse neuronal cell 
model, using HSV-1 mutants deficient for LAT, it was shown that LAT are not essential for 
establishment, maintenance and reactivation from latency (Javier, Stevens et al. 1988). A later 
study, also using HSV-1 mutants deficient for LAT, showed that the efficiency of reactivation 
from latency in this mouse model was reduced and that these mutants had an increased 
expression of E genes. LAT may play a role in suppressing the expression of IE transcripts 
(Chen, Kramer et al. 1997). In contrast, a study performed using a rabbit neuronal cell model 
showed that HSV-1 mutants deficient for LAT had a decreased expression of lytic transcripts, 
suggesting that LAT increase expression of these transcripts (Giordani, Neumann et al. 2008). A 
clear function regarding regulation of the expression of lytic genes cannot yet be attributed to 
LAT. The role of LAT in the maintenance of latency in HSV-1 may be related to the ability to 
inhibit apoptosis in the latently infected neurons, as cell lines are more resistant to cell death 
when LAT are expressed (Nicoll, Proença et al. 2012).  It has been demonstrated that BoHV-1 
encodes a latency related protein with anti-apoptotic functions (Perng, Maguen et al. 2002). 
Aside from the LAT expression during latency, the idea that latently infected cells do express 
some viral proteins could also account for the maintenance of latency. There is evidence of the 
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presence of HSV-1-specific activated CD8
+ 
T cells surrounding latently infected tissues 
(Decman, Kinchington et al. 2005). This evidence could support the dynamic theory of 
establishment of latency.  
Another line of investigation discovered a novel neuronal expressed protein called 
Zhangfei that has the ability to inhibit HSV-1 VP16 activation of IE genes (Akhova, Bainbridge 
et al. 2005). The same group had previously established that an ER related protein, Luman, could 
interact with the cellular protein HCF that is required in the cell nucleus to bind to VP16 for IE 
gene activation. They showed that in cells expressing Luman, HCF was relocated to the 
cytoplasm and that those cells were resilient to HSV-1 lytic infection, suggesting a role for 
Luman in latency establishment. Interestingly, it was also shown that Luman can activate the 
ICP0 promoter and the LAT promoter, suggesting an important role for Luman in reactivation of 
HSV-1 from latency (Lu and Misra 2000). 
1.5.2 Reactivation from latency  
As for establishment of latency, several theories have been proposed for virus 
reactivation from latency. The exact origin of the molecular process that triggers reactivation 
from latency is still uncertain, but the broad term “stress” has been applied for years (Preston 
2008). When referring to human alphaherpesviruses, reactivation of HSV-1 by stress is a well 
know example. Latent HSV-1 infection reactivates frequently in humans under psychological or 
physiological stress and the reactivation is detected as a proliferative/ulcerative epithelial lesion, 
usually in or around the oral cavity. The molecular events leading to the clinical sign lesions of 
reactivation have not been completely elucidated. Using in vivo mouse and rabbit models, a 
number of triggers, such as hyperthermia, tissue damage, immunosuppression, UV light 
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exposure and physiological stress have been used to induce reactivation of HSV-1 but not 
reactivation of VZV (Nicoll, Proença et al. 2012). Dexamethasone treatment at higher than 
therapeutic doses has been used to reactivate BoHV-1 and EHV-1 in rabbits and horses, 
respectively (Edington, Bridges et al. 1985; Rock, Lokensgard et al. 1992). At the cellular level, 
the stimuli that have been shown to reactivate HSV-1 in an in vitro neuronal model include 
hyperthermia, deprivation of nerve growth factor, inhibitors of histone deacetylase, and 
dexamethasone (Nicoll, Proença et al. 2012).  
One theory of reactivation proposes that stress causes, at the neuronal level, a shift in the 
transcription factor pattern with stimulation of the ICP0 promoter, synthesis of ICP0 protein and 
consequent deactivation of repression of the entire viral genome. In this context, ICP0 is 
proposed as a key player in the reactivation process in vitro (Nicoll, Proença et al. 2012). 
However, studies in mice infected with ICP0 mutants or wild type HSV-1 showed that the 
efficiency of reactivation following a  stimulus such as hyperthermia was similar, proving that 
ICP0 is not required to trigger reactivation in vivo (Thompson and Sawtell 2006). A recent study 
by Kim and colleagues presented novel insights regarding reactivation in vitro (Kim, Mandarino 
et al. 2012). Using cultures of latently HSV-1-infected primary superior cervical ganglion (SCG) 
sympathetic neurons, the authors characterized the expression of lytic genes after 
pharmacological induction of reactivation. A reactivation program divided into 2 phases was 
described. In a first phase, around 20 h after induction, there was expression of all lytic gene 
classes (IE, E and L) simultaneously, suggesting that deactivation of repression of the viral 
genome occurs without the need for viral proteins. At 48 h after induction a second phase with 
viral genome and virion production took place. Interestingly, the authors found that the 
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transactivating activity of VP16 was required for the second phase, suggesting that VP16 is a 
determining factor for reactivation.  
The other theory proposed for reactivation is related to the immunosuppression imposed 
by stress. As stated previously, the presence of HSV-1 specific CD8
+ 
cells surrounding latently 
infected tissues has been described (Kinchington, St Leger et al. 2012). If those cells normally 
prevent reactivation of latent virus, events leading to a temporary inhibition of the CD8
+ 
cell 
function could allow the propagation of the reactivated infection that normally would be 
restrained (Preston 2008; Kinchington, St Leger et al. 2012).  
1.6 Latency and reactivation of EHV-1 
1.6.1 Prevalence of latent EHV-1 infection  
The first studies that attempted to detect viral genomes in asymptomatic horses estimated 
that 30% of horses were latently infected (Edington, Welch et al. 1994; Allen 2006; Allen, Bolin 
et al. 2008). Two studies conducted in Kentucky (Allen, Bolin et al. 2008) and California 
(Pusterla, Mapes et al. 2010) obtained estimates of latent infections of 54% and 15%, 
respectively, by detecting viral DNA using two different techniques with comparable analytic 
sensitivity. In the Kentucky study, submandibular lymph nodes (SMLN) from 132 Thoroughbred 
broodmares were analyzed using an ultrasensitive magnetic bead-based, sequence capture, nested 
PCR technique. The California study used 2 sources of tissue (SMLN and trigeminal ganglia) 
from 147 horses of different breeds, four mules and two donkeys and the detection technique was 
a real-time TaqMan® PCR. The second study commented that when using highly sensitive 
detection techniques, contamination with EHV-1 DNA of the equipment and samples can lead to 
false positives and needs to be prevented. A previous publication from an author of the first 
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study (Allen 2006) had reported the high efficacy of the magnetic bead, sequence-capture, nested 
PCR to detect latent EHV-1 from mandibular lymph nodes samples collected antemortem, 
compared to conventional nested PCR and real time PCR. Using the new PCR technique, EHV-1 
DNA was detected in 8 out of 12 horses with unknown EHV-1 status and in 18 out of 24 
experimentally infected animals. For all three studies, (Allen 2006; Allen, Bolin et al. 2008; 
Pusterla, Mapes et al. 2010) negative controls were used to assure that no active infection was 
present in the samples. The discrepancy in the reported prevalence of latent EHV-1 infection 
could be explained by differences in geographical locations, management practices, horse breeds, 
PCR assays and more factors that may have not yet been considered (Lunn, Davis-Poynter et al. 
2009). Considering that there are limitations in the techniques to detect latent infection and an 
estimated 85% of horses have been exposed to EHV-1 by two years of age (Allen 2004), some 
reported  figures are also probably an underestimation and most horses should be considered to 
be latently infected (Lunn, Davis-Poynter et al. 2009).  
1.6.2 Establishment and maintenance of EHV-1 latency 
There is little information about the molecular events related to establishment and 
maintenance of latency of EHV-1. It has been suggested that after viral entry into host cells, 
EHV-1 can establish either a productive infection or enter a latent state, and both states 
apparently occur in parallel as viral replication does not seem to be a requirement for latency 
establishment in the neurons of the trigeminal ganglion (Sellon and Long 2007). Latency 
establishment in PBLs has also been described (Slater, Borchers et al. 1994; Sellon and Long 
2007). Within PBLs populations, the most frequent cell type harboring viral genome (detected by 
LAT expression) is the CD5
+
/CD8
+
 T lymphocyte (Chesters, Allsop et al. 1997). During latency, 
viral DNA adopts a circular conformation like other alphaherpesviruses, and expression of all 
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EHV-1 genes is repressed except for LAT that are located in an antisense region within the IE 
gene. There is no production of viral proteins, and latently infected cells remain “hidden” from 
the immune system. The molecular events that lead to establishment and maintenance of latency 
in EHV-1 have not yet been elucidated. The proposed theories for other alphaherpesviruses could 
potentially apply to EHV-1, taking into account the similarities and differences among the 
viruses. However, an in vitro model of equine origin to study establishment and maintenance of 
EHV-1 latency is still needed.  
1.6.3 Reactivation of EHV-1 from latency 
It is accepted that EHV-1 can establish latency in neurons of the trigeminal ganglion. 
Although establishment of latency in lymphoreticular tissues and PBLs has been proposed, in 
vitro experiments to detect EHV-1 reactivation from these sites have not produced conclusive 
results. (Gleeson and Coggins 1980; Scott, Dutta et al. 1983; Edington, Welch et al. 1994; Slater, 
Borchers et al. 1994; Chesters, Allsop et al. 1997; Smith, Iqbal et al. 1998).  
Between 1985 and 1994, Welsh Mountain ponies from closed herds or specific pathogen-
free pony foals were used for four EHV-1 latency and reactivation experiments. In the first 
study, eight Welsh Mountain ponies (five yearlings and three adults over 12 years of age) were 
infected and kept in isolation (as a group) for three months. Following the isolation period, the 
absence of active infection was demonstrated by a decrease in antibody titer for all animals and 
absence of virus in nasal secretions and leukocytes. All animals were then treated with 
immunosuppressive doses of dexamethasone (1mg/kg,) and prednisolone (2mg/kg). The authors 
reported viral recovery from nasal swabs and blood samples by co-cultivation with cell lines 
permissive to EHV-1 infection (EEK and RK-13) in six out of eight ponies. Three animals had 
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viremia without nasal shedding and two had viremia followed by nasal shedding. In one pony, 
virus was recovered from only one nasal swab. The authors suggested that the presence of 
viremia without nasal shedding could be interpreted as reactivation and that the detection of 
nasal shedding with or without the presence of viremia could be interpreted as potential EHV-1 
re-infection from other horses (Edington, Bridges et al. 1985). In the second study, two 
pathogen-free pony foals were inoculated twice, 61 days apart, and an additional two pathogen-
free pony foals were inoculated once at the same time as the second inoculation for the first 
group took place. Approximately 40 days after the second or only inoculation, respectively, all 
foals were given intravenous injections of dexamethasone (2mg/kg daily) for 3 consecutive days. 
Nasal mucus samples and blood samples were collected daily for 17 days after dexamethasone 
administration, co-cultivated with RK-13 cells for up to 1 week (nasal samples) or 2 weeks 
(isolated white blood cells) and re-plated if no viral plaques were observed. Virus was isolated 
from nasal mucus samples after dexamethasone treatment as follows: from the single inoculation 
group, one foal yielded virus on day 10 while virus was recovered from the other foal on days 5, 
8 and 10; from the double inoculation group, one foal yielded virus on day 12 while virus was 
recovered from the other foal on days 8, 10 and 12. In all positive cases, cell cultures needed to 
be re-passaged before cytopathic effects (CPE) were observed. Virus was not isolated from white 
blood cell samples (Gibson, Slater et al. 1992).  
In the third study, successful detection of viral DNA by PCR and reactivation of EHV-1 
by co-cultivation of lymphoid tissues collected post-mortem from five latently infected ponies 
was reported. The ponies, originally from a closed herd, had been experimentally infected 10 
weeks prior to euthanasia. Virus was grown by co-cultivation with EEK or RK-13 cells from the 
following tissue samples: PBLs, thymus, spleen, tonsil and retropharyngeal, submandibular, and 
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bronchial lymph nodes. Viral DNA was detected by PCR in all of the same tissues and, in 
addition, in the popliteal lymph nodes, lung, bronchoalveolar lavage fluid and ganglia of the 
trigeminal nerve. In three instances, samples positive by co-cultivation were negative by PCR, 
but in general, PCR was more sensitive for virus detection than co-cultivation. The authors 
determined that all ponies were latently infected only by PCR detection of viral genome, while 
one pony was consistently negative by co-cultivation. It is interesting that these authors were not 
able to reactivate EHV-1 from neuronal ganglia while they did detect viral DNA in neuronal 
ganglia in one pony by PCR (Welch, Bridges et al. 1992).  
The fourth study showed that latent EHV-1 could be reactivated from the trigeminal 
ganglion (Slater, Borchers et al. 1994). Four EHV-free SPF ponies were experimentally infected 
with EHV-1. Eight weeks later, reactivation of the virus from latency was induced by treating 
one pony with dexamethasone, one pony with cyclophosphamide (5mg/kg/day) and two ponies 
with cyclosporine A (10mg/kg/day) intravenously for three days. The ponies treated with 
cyclosporine A did not show reactivation and were treated 25 days later with dexamethasone 
(2mg/kg/day for three days). Viral reactivation in all four ponies was demonstrated by detection 
of high viral titers of EHV-1 in nasal mucus via co-cultivation with RK-13 cells. Although 
leukocyte associated viremia could not be detected by co-cultivation of PBMC samples, three 
ponies tested positive for EHV-1 by nested PCR in PBMC samples. The nested PCR used in this 
study, which differentiates between EHV-1 and EHV-4, was more sensitive than other PCRs 
available at the time this study was conducted (Borchers and Slater 1993). Six weeks after the 
viral shedding induced by the reactivation stimulus had ceased and no virus was recovered from 
nasal mucus or PBMC samples, all four ponies were euthanized and necropsied. Samples were 
collected from a large number of tissues: submandibular, retropharyngeal, bronchial and 
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mediastinal lymph nodes, tonsils, spleen, thymus, conjunctiva, liver, nasal epithelium, trachea, 
lung, olfactory nerve (cranial nerve I), optic nerve (cranial nerve II), trigeminal nerve (cranial 
nerve V) and trigeminal ganglion, and the facial nerve (cranial nerve VII). Although horses were 
assumed to be latently infected because of successful virus reactivation six weeks earlier,  post-
mortem samples (nasal tissue and trigeminal ganglion) from only two ponies showed virus 
reactivation by co-cultivation. However, samples of the trigeminal ganglion and the 
submandibular lymph nodes from all four ponies tested positive for EHV-1 by PCR. Viral 
detection by PCR in the rest of the lymphoid tissues was not consistent in the four ponies, but 
three out of four PBMC samples tested positive (Slater, Borchers et al. 1994).  
In addition to the in vivo reactivation studies in Welsh Mountain ponies, other studies 
have examined the prevalence of latent equine herpesvirus (1 and 4) infection in samples from 
40 horses collected from abattoirs (Edington, Welch et al. 1994). Samples were analyzed by 
PCR, differentiating between EHV-1 and EHV-4 (Welch, Bridges et al. 1992), and by co-
cultivation without discrimination between viruses. The tissues that showed the highest 
prevalence of latent EHV-1 infection by co-cultivation were the submandibular (35/40), 
retropharyngeal (25/40) and bronchial (22/40) lymph nodes. All positive co-cultivated samples 
were positive after the second passage. The nasal mucosa and trigeminal ganglion samples did 
not show viral reactivation in any sample. The authors commented that circulating mononuclear 
cells were collected from 20 horses; however, no results were published in this report. Further 
differentiation between viruses by indirect immunofluorescence in 22 samples from the same 
study showed that EHV-1 alone was present in 14% of the samples, EHV-4 alone was present in 
36% of the samples, and both viruses were present in 50% of the samples. The authors also 
reported that 87.5% of bronchial lymph nodes were positive by PCR detection, of which 32.5% 
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contained both viruses, 30% contained only EHV-1 and 25% contained only EHV-4. Of the nine 
samples of trigeminal ganglion analyzed by PCR, four tested positive to EHV-4 only, one tested 
positive to EHV-1 only and three tested positive to both viruses. Overall, the authors concluded 
that the main sites of latency for both EHV-1 and EHV4 are the lymph nodes of the respiratory 
tract and that the prevalence of latent equine herpesviruses is high in the equine population 
(Edington, Welch et al. 1994).  
The same authors, in 1997, reported the detection of EHV-1 LAT in equine leukocytes 
collected from bronchial lymph nodes and peripheral blood but they were not able to detect these 
transcripts in trigeminal ganglia. The samples used to detect LAT were from abattoir horses and 
from known latently infected ponies used in the reactivation experiment that was published in 
1985 (Chesters, Allsop et al. 1997).  
In 1998, Smith and colleagues reported the first chemically induced in vitro reactivation 
of latent EHV-1 from peripheral blood leukocytes and also identified the main type of latently 
infected leukocyte to be CD5
+
/CD8
+
. These authors investigated in vitro induction of 
reactivation following treatment of PBLs with mitogens, hormones and cytokines. They found 
that treatment of PBLs isolated from whole blood samples with phytohaemagglutinin (PHA), 
pokeweed mitogen (PWM), human interleukin 2 (IL-2) and equine chorionic gonadotrophin 
(eCG) for 24 h could induce EHV-1 reactivation. IL-2 is an immune cytokine secreted by the T-
lymphocytes and eCG is a hormone released by the gravid uterus, while PWM and PHA are 
mitogens derived from plants. Reactivation was detected by indirect immunofluorescence (IIF) 
targeting EHV-1 gB and by co-cultivation with EEK and RK-13 cells. The authors described that 
detection of reactivating virus by co-cultivation required at least 10
6
 leukocytes. RT-qPCR 
targeting EHV-1 gB transcripts was performed on RNA isolated from leukocytes exposed for 24 
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h to IL-2 or PHA, and showed positive results. The authors further identified by IIF that the cells 
harbouring reactivated virus were 80% CD5
+
/CD8
+
 and 20% CD5
+
/CD8
-
/CD4
-
. The mechanisms 
by which IL-2 and eCG can induce reactivation are independent. Reactivation after treatment 
with IL-2, PHA or PWM was blocked after addition of IL-2 antibodies, and eCG antibodies 
could block reactivation induced by eCG. IL-2 antibodies did not block eCG induced 
reactivation and eCG antibodies did not block IL-2 activation. Reactivation was achieved after 
treatment of whole leukocyte preparations with those chemicals, but could not be achieved in 
purified T-lymphocytes (CD3
+
 cells). However, virus reactivation in purified CD3
+
 cells could 
be accomplished if supernatant from stimulated whole leukocyte preparations was added to the 
culture. This showed that viral reactivation induced by eCG and IL-2 was accomplished by 
stimulation of CD5
+
/CD8
+
 cells and that activated CD5
+
/CD8
+
 cells produced substances that 
induced reactivation in other cell types.  
It has been suggested (Scott, Dutta et al. 1983; Edington, Bridges et al. 1985) that, as a 
result of sporadic reactivation of EHV-1 in latently infected PBLs, the virus reaches the 
respiratory epithelium, the pregnant uterus and endothelial cells in the CNS, establishing 
infection, viral shedding, viremia and, in some cases, clinical disease (Smith, Iqbal et al. 1998; 
Allen 2004). A shift from a non-productive to a productive infection, meaning reactivation from 
latency, is prompted in response to specific triggers that involve viral, endogenous and 
exogenous factors (Chesters, Allsop et al. 1997). Different types of stress have been proposed to 
be involved in reactivation from latency. The use of drugs, such as high doses of dexamethasone 
has been proved to cause reactivation (Edington, Bridges et al. 1985).  
While various physiological and physical stressors can reactivate EHV-1, it is still 
unclear how reactivation results in the rapid spread of the virus to susceptible horses within the 
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herd. In a more recent attempt to reactivate EHV-1 in latently infected animals using 
dexamethasone, it was found that one out of four horses showed fever while all four treated 
animals allowed low grade and transient molecular-based detection of EHV-1 in blood and nasal 
secretions, with negative viral isolation by co-cultivation (Pusterla, Hussey et al. 2010). 
However, housing the treated horses with EHV-1 seronegative sentinel horses did not result in 
infection of the sentinel horses. There was no development of clinical signs, viral recovery from 
any sample, viremia detection or seroconversion in any of the sentinel horses. For the 
dexamethasone treatment of these animals, although longer in time (5 consecutive daily 
treatments), the doses used (0.2-0.3mg/kg) were considerably lower compared with previous 
studies. Other postulated stressors such as hospitalization (Carr, Schott et al. 2011) or transport 
over long distances (Pusterla, Mapes et al. 2009) have failed to result in reactivation. To date, the 
molecular mechanisms of EHV-1 reactivation have not been elucidated.    
 
1.7 The unfolded protein response 
1.7.1 Protein folding in eukaryotic cells  
Proteins are macromolecules that depend on the final three-dimensional conformation to 
become biologically active (Anfinsen 1973). Synthesis of proteins involves transcription of 
genes in the nucleus and ribosomal translation either in the cytoplasm or in the endoplasmic 
reticulum (ER) (Warner 1963 ), an intricate phospholipid membrane system that is present in all 
eukaryotic organisms (Healy, Gorman et al. 2009). Synthesis of soluble proteins to be secreted or 
directed to the cellular membrane takes place in the ER membrane, where the secretory pathway 
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starts (Caro and Palade 1964 ). Such polypeptides must express a targeting signal to be directed 
to the ER (Allison and Young 1989). 
 The product of translation is a linear polypeptide chain in its primary conformation, 
meaning that it is not biologically active. The nascent polypeptide still attached to the ribosome 
or the completely translated polypeptide must be translocated into the ER lumen in order to be 
folded, processed and glycosylated. The oxidizing luminal environment of the ER is 
characterized by a high concentration of chaperone proteins and high calcium concentration, as 
most of these chaperone proteins are calcium dependent (Lièvremont, Rizzuto et al. 1997). 
Chaperone proteins assist the transport of the nascent polypeptide chain into the ER, and they 
also assist the folding process by stabilizing the peptide, preventing premature folding and 
avoiding protein aggregation (Beckmann, Mizzen et al. 1990). The glucose regulated protein 
78KDa/ immunoglobulin heavy chain binding protein (GRP78 or BiP) is a chaperone protein 
present in the ER of all cells, which plays a fundamental role in protein folding, quality control 
and some translocational processes (Haas and Wabl 1983; Munro and Pelham 1986; Hendershot, 
Ting et al. 1988). The folding process shapes polypeptides into an active/functional state that is 
then targeted for transportation and finally delivered to its definitive location. During the folding 
process, misfolding of polypeptides can occur under normal conditions. Misfolded proteins can 
either be refolded in the ER lumen or targeted for degradation. ER processes only take place 
under normal and optimal conditions; if these conditions are distorted, the influx of new 
unfolded, immature proteins into the ER is reduced, primarily to ensure the cell’s survival and 
eventually to re-establish the normal post-translational modification process (Kim, Xu et al. 
2008).  
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1.7.2 ER stress signaling: activation of the unfolded protein response 
Under normal, homeostatic conditions the chaperone protein GRP78 is bound to the 
luminal portion of an ER group of transmembrane proteins, and also binds to the incoming 
unfolded or misfolded proteins that will be modified in the ER. When the influx of unfolded 
proteins into the ER lumen is higher than the capacity of the ER to process and modify those 
proteins, GRP78 is forced to bind to the increasing number of unfolded proteins, consequently 
releasing its bond to the luminal portion of transmembrane regulatory proteins and initiating a 
signaling cascade known as the unfolded protein response (UPR)(Healy, Gorman et al. 2009).  
The UPR is an evolutionarily conserved response triggered by the accumulation of 
unfolded and misfolded proteins in the ER. Different stimuli can alter cellular homeostasis, 
induce ER stress and, consequently, interrupt the protein folding process generating 
accumulation of unfolded and misfolded proteins. Conditions such as hypoxia, glucose 
deprivation, oxidative stress, disequilibrium in calcium concentration, viral infection and 
neoplastic cellular modifications can induce ER stress and UPR activation. The UPR 
communicates to the nucleus the folding status of proteins in the ER lumen to orchestrate a 
highly regulated response. Depending on the duration, intensity and origin of the stress stimulus, 
the UPR can proceed to different outcomes. There is an initial adaptive response that can be 
separated into an immediate reaction and a secondary reaction. The immediate reaction’s 
purpose is to decrease the translation and transport of new polypeptides into the ER. The 
secondary reaction’s objective is to induce the expression of genes that either help in the 
adaptation to stress or, failing that, induce apoptosis. When the ER fails to adapt to the stress or 
the UPR fails to restore normal ER function, an alarm response is activated to notify the cell and 
its surrounding of the abnormal situation by linking with several cellular pathways (Yoneda, 
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Imaizumi et al. 2001; Kato, Nakajima et al. 2011). Eventually, if this response fails to restore ER 
function, the apoptotic phase is triggered, leading to programmed cell death (Hetz 2012) (Kim, 
Xu et al. 2008). The activation of the UPR results in a number of mechanisms to decrease the 
presence of unfolded proteins in the ER lumen: prevention of the influx of more 
unfolded/misfolded proteins into the ER, induction of the expression of UPR-related genes, and 
physical expansion of the ER membrane (Shaffer, Shapiro-Shelef et al. 2004) that ultimately 
enhances the folding capacity, the quality control system and the ER-associated degradation 
capacity. The UPR signaling mechanisms are based mainly on the release of GRP78 from three 
transmembrane proteins: Inositol–requiring kinase 1 α (IRE1α), Pancreatic ER kinase (PKR)-like 
ER kinase (PERK) and Activating transcription factor 6 (ATF6) (Figure 1.3). 
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Figure 1.3 Activation of the UPR upon ER stress. During homeostatic conditions, GRP78 
binds IRE1α, ATF6 and PERK, preventing their activation. Upon ER stress, the increased influx 
of misfolded proteins displaces GRP78 from the membrane position and activates the signaling 
cascade. IRE1α homodimerization induces its own autophosphorylation and activates its 
endoribonuclease activity that splices XBP1 mRNA. ATF6 undergoes translocation to the Golgi 
complex and cleavage. PERK homodimerization induces its own autophosphorylation, 
phosphorylation of eIF2α and induction of ATF4. Activation of the 3 arms of the UPR induces 
transcription of UPR related genes in the nucleus.  
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1.7.2.1 Activating transcription factor 6 (ATF6) 
ATF6 is a protein from the family of cAMP response element binding (CREB) 
transcription factors (Yoshida, Haze et al. 1998; Hai and Hartman 2001). It is localized in the ER 
membrane. ATF6 possesses a basic leucine zipper (bZIP) and a transcription activation domain 
in its cytosolic portion (Asada, Kanemoto et al. 2011). After dissociation of GRP78-ATF6 
binding, ATF6 is released from the ER membrane and is translocated into the Golgi, where it is 
cleaved by the Site 1 and Site 2 protease system and the bZIP domain is translocated to the 
nucleus (Shen, Chen et al. 2002). The bZIP domain binds to ER stress response elements 
(Yoshida, Haze et al. 1998) and induces transcription of UPR related genes. Some of the 
downstream targets of ATF6 activation are: ER chaperone proteins GRP78, GRP94 and 
calreticulin, XBP1, and Protein disulfide isomerase (PDI)  (Hsu, Hsieh et al. 2005; Kim, Xu et al. 
2008).  
A number of ER localized, ER stress-related proteins with high ATF6 homology have 
been described: Luman (CREB3) (Lu, Yang et al. 1997); OASIS (CREB3L1) (Kondo, 
Murakami et al. 2005); CREB3L2 (Kondo, Saito et al. 2007); CREB3L3 (Zhang, Shen et al. 
2006) and CREB4 (CREB3L4) (Nagamori, Yabuta et al. 2005). Many of these proteins have 
been shown to activate the UPR and are believed to replace or supplement the activity of ATF6 
in some cells. Most of these transcription factors are expressed in specific cells. For instance, 
Luman mRNA has been found in various cell types but Luman protein translation appears to be 
specific to neuronal tissues (Asada, Kanemoto et al. 2011). It was shown that Luman induces 
HERP (homocystein-inducible ER stress inducible ubiquitin like domain member 1) and ER-
associated protein degradation (Liang, Audas et al. 2006). Luman has been found to contribute to 
neuronal repair upon sensory nerve injury (Ying, Misra, Verge, submitted). Knowledge of the 
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role of Luman as a stress response protein and its involvement in the UPR has increased 
enormously in the last years, as studies in this area progress. Luman activation is inhibited by 
another neuronal protein, Zhangfei (Misra, Rapin et al. 2005). Zhangfei also has the ability to 
suppress the UPR activation by other means independently of Luman (Bergeron, Zhang et al. 
2012). 
1.7.2.2 Inositol requiring kinase 1 α (IRE1α) 
IRE1α is a transmembrane protein localized in the ER membrane. It possesses a kinase 
domain and mRNA endoribonuclease activity in its cytosolic domain (Tirasophon, Welihinda et 
al. 1998). After GRP78 dissociation, IRE1α homodimerization activates the kinase domain that 
induces autophosphorylation and transphosphorylation that further activates its mRNA 
endoribonuclease activity. Activation of IRE1α endoribonuclease activity splices XBP1 (X-box 
binding protein) mRNA, giving rise to the XBP1 spliced form, which is now translated to XBP1s 
protein, a bZIP transcription factor that binds to the ER stress response element and promotes the 
transcription of target UPR genes (Bertolotti, Zhang et al. 2000; Yoshida, Matsui et al. 2001). 
IRE1α also has the ability to degrade specific mRNAs different from the XBP1 mRNA in a 
regulated IRE1 dependant decay (RIDR) (Hollien and Weissman 2006), and it is a key player in 
the alarm response and in the cross talk with cellular pathways by activating JNK (c-Jun N-
terminal kinase) and NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
(Hetz 2012). Some of XBP1s targets are: CHOP (DNA damage inducible transcript 3), a pro-
apoptotic gene; HERP and EDEM (ER degradation enhancing α mannosidase like protein) genes 
related to the ER associated protein degradation, and p58IPK, an inhibitor of PERK (Ma and 
Hendershot 2004; Hetz 2012). 
 39 
 
1.7.2.3 Pancreatic ER kinase (PKR)-like ER kinase (PERK)  
PERK, as IRE1α, is an ER resident transmembrane protein with a serine/threonine kinase 
domain. Under ER stress it dissociates from ER luminal binding to GRP78. Homodimerization 
and auto trans-phosphorylation activates its kinase activity. PERK phosphorylates the eukaryotic 
translation initiation factor 2α (eIF2α), thereby inactivating it (Bertolotti, Zhang et al. 2000). 
Phosphorylation of eIF2α causes the inhibition of cap-dependant mRNA translation, generating a 
change to a cap-independent translation of mRNA containing the internal ribosome entry site 
(IRES) sequence (Hanson, Zhang et al. 2013), therefore reducing the load of incoming proteins 
into the ER. However, there is a selective translation of some mRNA, including the activating 
transcription factor 4 (ATF4) mRNA. ATF4 increases chaperone levels by inducing XBP1 
expression, and also induces genes related to redox balance, amino acid metabolism and 
autophagy, seeking to restore ER homeostasis. PERK activation also induces and up-regulates 
apoptotic signals such as CHOP (Healy, Gorman et al. 2009) and induces the expression of 
growth arrest and DNA damage-inducible protein (GADD34) which associates with a protein 
phosphatase 1(PP1) to dephosphorylate eIF2α as a feedback loop auto-regulating PERK 
activation (Brush, Weiser et al. 2003).   
It is important to note that upon activation of the UPR, the two different phases that take 
place in a cell, namely the adaptive phase and the apoptotic phase, are programmed to occur in 
temporal fashion, one after the other. It would be expected that expression of UPR related genes 
followed that same pattern. However, when gene expression assays are performed, the adaptive 
phase genes and the pro-apoptotic genes are found to overlap in time. In most of the in vitro 
experiments performed to study the UPR, chemical inducers of ER stress are used in 
concentrations and durations that are detrimental to cells in such a way that the cells are 
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condemned to death. In contrast, cells exposed to physiological stress can regulate the UPR and 
survive, or even adapt to UPR activation for prolonged periods of time, as is the case with 
secretory cells (Hetz 2012).      
1.8  Regulation of the UPR during viral infection 
When a virus infects a cell, it depends on the cellular machinery to synthesize viral 
proteins. This means that a virally infected cell will be suddenly forced to increase its protein 
production. As described earlier, one of the stressors that can trigger activation of the UPR is 
viral infection. Activation of the UPR is a major obstacle for viral infection as it leads to 
shutdown of protein translation. Also, prolonged activation of the UPR leads to apoptosis of the 
host cell, which would also stop virus production. To get around these obstacles, viruses have a 
number of strategies to manipulate the UPR. Several of these methods have been described in the 
literature for different viruses.  
Hepatitis C virus (HCV) is a member of the Flaviridae family and possesses 2 envelope 
proteins (E1 and E2) that have been found to induce expression of ER chaperone proteins 
GRP78 and GRP94 (Liberman, Fong et al. 1999). Later, it was described how replication of 
HCV triggered activation of the UPR but selectively decreased the phosphorylation of eIF2α by 
PERK inhibition, mediated by binding of the E2 protein (Tardif, Mori et al. 2002; Pavio, 
Romano et al. 2003). The HCV proteins E1 and E2 were found to induce the CHOP promoter 
and the splicing of XBP1, probably by IRE1α activation (Chan and Egan 2005). In contrast, one 
study showed that HCV can suppress the activation of IRE1 (Tardif, Mori et al. 2004), while 
another study described how an ER membrane associated viral protein, NS4B, induces UPR 
activation, cleavage of ATF6 and splicing of XBP1 (Li, Ye et al. 2009).  
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Another member of the Flaviridae family, West Nile virus (WNV), regulates UPR 
activation as it strongly induces the IRE1α pathway while regulating activation of the PERK 
pathway (Ambrose and Mackenzie 2011). However, there is disagreement with previous studies 
that proposed that WNV infection triggered activation of the UPR with a strong induction of 
CHOP (a downstream target of PERK activation) and subsequent UPR driven apoptosis 
(Medigeshi, Lancaster et al. 2007). Differences could be attributable to the viral strains used in 
the studies. The hypothesis of apoptosis induction by WNV seems plausible as it has been 
described that a member of the Picornaviridae family, Coxsackievirus B3 (CVB3), induces 
strong CHOP expression and apoptosis (Zhang, Ye et al. 2010) and a member of the Togaviridae 
family, Semliki Forest virus (SFV), also induces UPR driven apoptosis by up-regulation of 
CHOP expression (Barry, Fragkoudis et al. 2010).  
Hepatitis B virus (HBV) a member of the Hepadnaviridae family has been shown to 
induce expression of UPR chaperones by the over expression of the viral Large Surface Protein, 
and hepatitis B virus X protein (HBx) has been shown to activate the ATF6 and IRE1α pathways 
of the UPR (Xu, Jensen et al. 1997; Li, Gao et al. 2007).  
In the Herpesviridae family, Cytomegalovirus (CMV) (a member of the subfamily 
Betaherpesvirinae), has been described to selectively regulate the UPR to its benefit. The viral 
protein pUL38 was found to strongly activate the PERK pathway, resulting in elevated ATF4 
expression and phosphorylation of eIF2α, while suppressing activation of the JNK pathway 
mediated by IRE1α, both resulting in rescue of the cell from apoptosis (Xuan, Qian et al. 2009). 
At the same time that CMV infection induces expression of GRP78, inhibition of GRP78 was 
shown to stop the assembly of CMV (Buchkovich, Maguire et al. 2009).  
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Kaposi's sarcoma-associated herpesvirus (KSHV or Human herpesvirus 8), a member of 
the subfamily gammaherpesvirinae, has been found to increase expression of ATF4 upon 
infection of cells. As both ATF4 and XBP1 are inducers of viral replication, induction of ER 
stress and UPR activation could play a role in viral reactivation from latency (Wilson, Tsao et al. 
2007; Caselli, Benedetti et al. 2012). In contrast to these reports, one study showed that treatment 
of KSHV-infected cells with non-toxic doses of the glucose analog 2-deoxy-D-glucose (2-DG) 
led to inhibition of N-linked glycosylation with further UPR activation. Interestingly, PERK- 
mediated UPR activation caused the shutdown of protein translation, inhibition of lytic gene 
expression and inhibition of viral reactivation (Leung, Duran et al. 2012).   
The interaction between alphaherpesviruses and the UPR has been evaluated in VZV and 
HSV-1. Regarding VZV, Carpenter and colleagues described the enlargement of the ER as a sign 
of ER stress with a 10-fold increase occurring in infected as opposed to uninfected cells. 
Increased splicing of XBP1 and increased expression of CHOP in virus-infected cells was 
described. UPR activation appears to modulate ER stress in VZV infected cells and spare them 
from apoptosis. It is interesting to note that in this study, it was proposed that autophagy in VZV 
infected cells is a pro-viral event, which is in contrast to the viral inhibition of autophagy in 
HSV-1 infection that serves to ensure virus survival (Carpenter, Jackson et al. 2011). It has been 
suggested that while HSV-1 activates PERK, this activation is counteracted by indirect 
dephosphorylation of eIF2α mediated by the viral protein γ134.5 and the consequent derepression 
of protein translation (Cheng, Feng et al. 2005). A later report showed that HSV-1 glycoprotein 
B physically interacts with PERK, thereby inhibiting its activation and regulating the PERK 
pathway (Mulvey, Arias et al. 2007). A more recent study investigated the expression of the UPR 
during early HSV-1 infection (Burnett, Audas et al. 2012). It was shown that during the first 24 h 
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after infection, HSV-1 induces transcription of UPR genes through ER stress-responsive 
elements in their promoters. It was also confirmed that the ATF6 arm of the UPR was active 
between 2 and 8 h after infection and was later suppressed. Phosphorylation of eIF2α was shown 
to be decreased from 2 to 8 h and to increase at 24 h after infection. ATF4 and CHOP showed a 
similar expression pattern with suppression in the early stages and induction in the late stages. 
The IRE1α arm was also suppressed during the first 24 h after infection. Interestingly, the viral 
gene ICP0 promoter is responsive to ER stress and it may act as a stress detector on behalf of the 
virus. It was determined in this study that HSV-1 can silence the UPR during early infection and 
modulate it in its favour (Burnett, Audas et al. 2012). 
1.8.1 UPR involvement in herpesvirus latency and reactivation (rationale for examining 
the UPR as a potential trigger for EHV-1 reactivation) 
A variety of seemingly unrelated stressors are known to trigger the reactivation of 
herpesviruses from latency.  However, a common molecular pathway that would focus the 
effects of these stressors to the latent herpesvirus genome has not been identified. Since the UPR 
is activated by a variety of stressors, such as inflammation, hypoxia, an increase in protein 
synthesis, neuronal injury etc. (many of these are known herpesvirus reactivators) I speculate 
that herpesviruses use the UPR as a means of sensing stress in their hosts. Indeed, Wilson and 
others (2007) have linked Xbp1s, an important UPR mediator, to the reactivation of Kaposi 
sarcoma herpesvirus from latently infected plasma cells. In addition, our laboratory has 
discovered two basic-leucine motif containing transcription factors that can regulate the UPR as 
well as the HSV lytic cycle. Luman/CREB3 (Lu et al, 1997, 1998) is an ER-associated protein 
that is released from the ER in response to stress (Raggo et al. 2002), such as damage to 
peripheral nerves (Ying, Misra, Verge, submitted). It then enters the nucleus to activate gene 
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expression. Luman resembles the UPR mediator, ATF6 and can transactivate the expression of 
UPR genes (DenBoer et al, 2005; Liang et al. 2006). Luman can also substitute for the HSV 
transactivator VP16 for initiating the HSV lytic cycle (Lu and Misra, 2000). In contrast, the other 
neuronal protein, Zhangfei/CREBH (Lu and Misra, 2000), can very effectively shut off the UPR 
(Zhang et al, submitted), Luman (Misra et al. 2005) as well as the initiation of the HSV lytic 
cycle by VP16 or Luman (Akhova et al. 2005). These observations, that Luman and Zhangfei 
can influence the UPR as well as HSV replication in sensory neurons, the seat of HSV latency, 
have led us to suggest that HSV regulates latency and reactivation by using the UPR (specifically 
Luman and Zhangfei) as sensors of stressful and non-stressful conditions (Fig 1.4). 
Since Luman (Kang et al. 2009; Kim et al, 2010; Fox, 2010) and Zhangfei (Misra et al, 
2012; Zhang et al., 2010; Lopez-Mateo et al. 2012) are also thought to regulate the UPR and 
stress responses in tissues other than neurons, I extended our proposed model to PBLs, the 
proposed site of EHV-1 latency.  
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Figure 1.4. A model proposing the involvement of the UPR, specifically Luman and 
Zhangfei, in the establishment of herpesvirus latency and reactivation from it. Both 
Zhangfei and Luman (anchored in the ER in an inactive state) are present in unstressed 
differentiated cells such as sensory neurons and as yet unidentified lymphoid cells in the 
peripheral blood. Zhangfei, in this state modulates the UPR (which, if unrestrained, can trigger 
apoptosis) and inhibits the replication of herpesviruses that might infect the cell. The suppression 
of the herpesvirus lytic cycle leads to latency, which is characterized by the expression of LAT. 
Stress (in many of its forms) releases Luman from the ER and the protein then activates the UPR. 
In cells harbouring latent herpesviruses Luman also initiates the herpesvirus lytic cycle leading 
to reactivation. 
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1.9 Hypothesis 
My overall hypothesis states that latent EHV-1 can be reactivated by activating the UPR 
in equine peripheral blood leukocytes (PBLs). This hypothesis is based on the assumption that 
EHV-1 establishes latency in PBLs, and that EHV-1 relies on the UPR as a pluripotent cellular 
stress sensor.  
1.9.1 Objectives 
To test this hypothesis I had the following objectives:   
 Objective 1: To establish a RT-qPCR assay that could be used to detect and quantitate 
down-stream UPR gene expression in equine cells, examine the UPR activation over a period 
of time in equine dermal cells and determine if the UPR can be activated in equine PBLs. 
 Objective 2: To characterize lytic EHV-1 infection in equine dermal cells and detect the 
expression of EHV-1 genes over time.  
 Objective 3: To investigate the relationship between EHV-1 gene expression and UPR gene 
expression during lytic infection of equine dermal cells. 
 Objective 4: To detect latent EHV-1 in PBLs from horses presumed to be latently infected 
and determine if stimulation of the UPR in these cells leads to virus reactivation.  
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2 DETECTION OF UPR GENE EXPRESSION 
My first objective was to establish a RT-qPCR assay that could be used to detect and 
quantitate down-stream UPR gene expression in equine cells, examine the UPR activation over a 
period of time in equine dermal cells and determine if the UPR can be activated in equine PBLs. 
Primers targeted to selected UPR related genes were designed and tested in equine 
dermal cells (E.Derm) treated with thapsigargin, a chemical compound that produces a calcium 
imbalance in the cells and induces ER stress. Genes that had been reported to respond to 
perturbations of ER function in other species such as humans and dogs, and that represented the 
3 arms of the UPR were selected (Table 2.1). These included the genes for: X-box binding 
protein 1 spliced (XBP1s), 78 kDa glucose regulated protein-like (GRP78), DNA damage-
inducible transcript 3 protein-like (CHOP), and homocysteine-responsive endoplasmic 
reticulum-resident ubiquitin-like domain member 2 protein-like (HERP). The equine-specific 
(Equus caballus) mRNA sequences for these protein products are available in GenBank; the 
accession numbers are listed in Table 2.1. 18s ribosomal RNA, which is a basic constituent of 
eukaryotic cells and has been described as a reliable reference gene for RT-qPCR (Allen, Payne 
et al. 2007) was selected  as the reference gene for this project. .  
The published guidelines for minimum information for the publication of data from RT-
qPCR experiments (MIQE) require that the PCR reactions be efficient and highly specific. The 
analytical specificity of the reaction is defined as the PCR assay detecting the appropriate target 
sequence rather than nonspecific targets that are also present in a sample (Bustin, Benes et al. 
2009). To confirm the specificity of the PCR reactions, I established the identity of the PCR 
products by determining their size, the kinetics of their dissociation over a range of temperatures 
and, ultimately, by determining their nucleotide sequence. I also strived to optimize the 
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efficiency of the reaction to ensure that the product doubled in quantity at each cycle of the 
reaction. 
 
2.1 Materials and Methods 
2.1.1 Equine dermal cell culture  
A cell line of equine dermal (E.Derm) cells with fibroblast morphology (NBL-6, ATCC® 
CCL-57™) was generously provided by Elaine Van Moorlehem from the Vaccine and Infectious 
Disease Organization (VIDO), University of Saskatchewan. E.Derm cells were grown and 
maintained in Minimum Essential Medium (MEM) supplemented with 2mM L-Glutamine 
(Fisher Scientific, Waltham, Massachusetts, USA), 1% MEM Non-Essential Amino Acids 
(NEAA, Invitrogen), 10mM HEPES (Invitrogen) and 0.1% gentamicin (Invitrogen). E.Derm 
cells were cultured in 6-well or 12-well culture plates (BD Falcon) and incubated in a 5% CO2 
humidified atmosphere at 37°C. Cells were allowed to grow for 2 days or until 80% confluence.  
2.1.2 Horses 
Six mares from the WCVM teaching herd were used to collect blood samples. These 
animals are used for teaching purposes in clinical laboratories and classes, and have no recorded 
history of EHV-1 infection. Procedures were approved by the Animal Research Ethics Board, 
University Committee on Animal Care and supply (UCACS), University of Saskatchewan, and 
followed the guidelines of the Canadian Council on Animal Care (CCAC). 
 49 
 
2.1.3 Blood Sampling, PBLs isolation and culture 
Blood samples (30 or 60ml) were collected in 10 ml Vacutainer® K2 EDTA Tubes (BD 
Falcon, New Jersey, USA). The blood was diluted 1:1 with Dulbecco’s Modified Eagle’s 
medium (DMEM, Invitrogen, Carlsbad, CA, USA). The PBLs were isolated using Lymphocyte 
separation medium (LSM, MP Biomedicals, California, USA) by layering 2.5 ml of LSM and  
5ml of diluted blood in 15 ml centrifuge tubes (BD Falcon) followed by 30 minutes of 
centrifugation at 800  g in a Sorvall Legend RT centrifuge (Thermo Scientific, Waltham, 
Massachusetts, USA). All the centrifugation steps were carried out at room temperature. After 
centrifugation, three clear layers could be distinguished. The middle layer was transferred to a 
fresh 15 ml tube containing 10 ml of DMEM followed by 7 minutes of centrifugation at 275  g. 
The supernatant was discarded and the pellet washed with 8 ml of DMEM. After 7 minutes of 
centrifugation at 150  g, the supernatant was discarded and the pellet resuspended in Roswell 
Park Memorial Institute Medium (RPMI 1640, Invitrogen). Trypan blue dye 0.4% in D-PBS 
(BDH Inc, Toronto, Canada) was added to the cell suspension to a final concentration of 0.08% 
to assess cell viability, and a haemocytometer chamber was used to count cells. Dead cells 
absorb the blue dye, while viable cells with intact membranes do not absorb it. PBLs were 
maintained in RPMI 1640 with 10% fetal bovine serum and 1% penicillin-streptomycin 
(Invitrogen). PBLs were maintained in 6 well culture plates or in 25 cm
2
 cell culture flasks (BD 
Falcon) and incubated in a 5% CO2 humidified atmosphere at 37°C.    
2.1.4 Polymerase Chain Reaction (PCR) 
All primers were purchased from Integrated DNA technologies (Coralville, Iowa, USA.). 
Primers for equine GRP78 and XBP1s genes were designed using the Primer3 (v.0.4.0) web site 
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(http://frodo.wi.mit.edu/) using the nucleotide sequences found in GenBank. General primer 
selection default conditions were maintained according to the software requirements with 
product size between 200 and 400 base pairs and primer size between 18 and 22 base pairs 
(Table 2.2). For assessing transcripts from equine HERP and CHOP genes, I used primers 
originally designed in Dr. Misra’s lab to amplify targets in the canine homologues of these 
genes.  
RNA (from E.Derm cells and PBLs) was purified using the RNeasy plus minikit (Qiagen) 
according to manufacturer’s instructions. The concentrations of DNA and RNA were measured 
using a Nanodrop 2000C spectrophotometer (Thermo Scientific). Complementary DNA (cDNA) 
synthesis was performed using the QuantiTect® reverse transcription kit (Qiagen) with 
integrated removal of genomic DNA contamination, according to instructions provided with the 
kit.  
Quantitative real time PCR (RT-qPCR) was performed in a Mx3005P QPCR thermal 
cycler (Stratagene, La Jolla, CA, USA). To quantify transcripts of interest, the Brilliant II 
SYBR
®
 Green QPCR Master Mix protocol (Agilent technology, Santa Clara, California, USA) 
was used. Samples were amplified using the following thermal cycler conditions: 95°C for 10 
min followed by 40 cycles of: 95°C for 30 s, 60°C for 1 min, 72°C for 1 min. Data were analyzed 
using the thermal cycler-associated software. The UPR (Table 2.2) and the TNF α (Table 2.4) 
primer sets for transcript amplification were used at a final concentration of 1.875 μM. The 
concentration of transcripts in each sample was expressed as the quantification cycle (Cq).  
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The efficiency of RT-qPCR reactions for each set of primers was determined from the 
slope of the standard curve developed with serial 4 fold dilutions of cDNA template. The PCR 
efficiency was calculated from the following equation(1).  
(1) Efficiency (E) = (10^(-1/slope)-1)*100    
The theoretical maximum of 100% indicates that the amount of product doubles with 
each cycle and an efficiency of between 95-150% is considered acceptable (Bustin, Benes et al. 
2009). Efficiency values greater than 150% could indicate that more than one product is 
amplified in the reaction. 
To assess the effect of cell stimulation, gene expression levels were normalized to the 
reference gene 18s and differences between treated and control samples expressed as fold 
change. Fold changes were calculated according to the 2
-∆∆Cq 
method (Livak and Schmittgen 
2001) as follows: The Cq value of the reference gene (18s) was subtracted from the Cq value of 
the gene of interest in the control sample (DMSO) to generate the ∆Cq value of the control and 
the same procedure was repeated for the treatment sample (thapsigargin) generating the ∆Cq of 
the sample. Then, the ∆Cq control was subtracted from the ∆Cq sample (∆Cq sample-∆Cq 
control) to generate the ∆∆Cq value, to finally calculate the fold change as 2-∆∆Cq. A minimum 
fold change value of 2 was arbitrarily assigned as a cut-off to demonstrate gene induction in the 
stimulated cells. 
2.1.5 PCR product purification and sequencing  
Double stranded DNA fragments from PCR reactions (the PCR products) were purified 
using the MinElute PCR purification kit (Qiagen) as per manufacturer’s instructions. Purified 
RT-qPCR products were mixed with 6x stop solution (1 part of 2.5% bromophenol blue (Sigma 
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Aldrich), 1 part of 2.5% xylene cyanol (Bio-Rad Laboratories), 3 parts of glycerol (Sigma 
Aldrich) and 5 parts of distilled water) and loaded onto a 2% agarose gel prepared with ultra-
pure agarose (Invitrogen) in 0.5X TBE buffer (Tris base, boric acid and EDTA in ultrapure 
water) and 5 μl of SYBR® Safe DNA free stain (Invitrogen). Gels were electrophoresed at 110 
volts until the dye front was within a few centimeters of the end of the gel. A 1kb plus DNA 
ladder (Invitrogen) was electrophoresed alongside the samples to estimate the size of the PCR 
products. DNA bands were visualized in an Alphaimager (Alpha Innotech Cell Biosciences 
Santa Clara, California, USA). 
Sanger sequencing of the PCR products using the UPR primer sets (Table 2.2) was 
performed by the Plant Biotechnology Laboratory, National Research Council, University of 
Saskatchewan, Saskatoon, SK, Canada. The sequenced products were matched to sequences 
published in  GenBank using the Basic Local Alignment Search Tool (BLAST) (Altschul, Gish 
et al. 1990) software available from the NCBI website (Table 2.3). 
2.1.6 UPR activation in E.Derm Cells       
Chemicals used for cell treatment were obtained from Sigma Aldrich (St. Louis, 
Missouri, USA). DMSO (Dimethyl sulfoxide) was used at a final concentration of either 0.4 μl 
or 0.8 μl per ml and thapsigargin (750μM in DMSO) was used at a final concentration of either 
300nM or 600nM.  
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Experimental design diagram  
 
 
 
                       
E.Derm cells were plated at 2x10
5 
in 6-well plates and grown until 80% confluence. 
 
The 
general design for this experiment was to induce ER stress in cultured E.Derm cells  by treatment 
with thapsigargin for 4 h (Bergeron, Zhang et al. 2012), followed by RNA isolation and RT-
qPCR to detect UPR gene expression. Cells incubated with DMSO were used as a negative 
control. Thapsigargin was the drug selected in this project to activate the UPR, because it was 
currently in use in our laboratory for other projects with successful results (Bergeron, Zhang et 
al. 2012). It has also been stated in the literature that “thapsigargin induces a more rapid and 
stronger UPR than tunicamycin" (Gülow, Bienert et al. 2002). 
To initially test the primers and validate the PCR products by sequencing, the treatment 
was 4h incubation with 300nM thapsigargin compared to DMSO control. In a second 
experiment, sample collection was modified to obtain information about the expression of the 
UPR genes over a period of time after inducing ER stress as one of the later objectives (objective 
3) of this project was to evaluate the effect of UPR activation on viral gene expression during 
replication of EHV-1. Considering that during lytic EHV-1  infection, transcripts of some  viral 
genes can be detected starting at 4 h post infection while others can be detected as late as 18 h 
post infection, the UPR was evaluated over a period of 18 h. Cells were treated at time 0 by 
RNA Isolation  
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t18 t8 t4  t0 
 
E.Derm Cells DMSO 
E.Derm Cells 600 nM 
Thapsigargin  
Media 
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adding 600 nM of thapsigargin or DMSO, treatment was removed and fresh media added at 4h, 
and cells were harvested at 4h, 8h or 18h following treatment for total RNA collection and RT-
qPCR to detect UPR gene expression. At each time point, the expression of each UPR gene after 
thapsigargin treatment was compared to the expression of the same gene in cells treated with 
DMSO, and expressed as fold change. The experiments were performed in duplicate and 
repeated on 9 different occasions. A higher concentration of thapsigargin was chosen for the 
second experiment because I found that using a higher dose did not have detrimental effects on 
the E.Derm cells.    
2.1.7 UPR activation in PBLs 
Experimental design diagram: 
  
 
In order to evaluate if UPR gene expression could be activated and measured in equine 
PBLs, the same UPR primers used in the E.Derm cell experiments plus a set for amplification of 
TNF mRNA were used (Table 2.4). Amplification of tumor necrosis factor α (TNFα) was used 
as described previously (Figueiredo, Salter et al. 2009) to evaluate a common PBLs gene 
transcript that is induced by cellular stress (Table 2.4). It was used as a positive control of PBLs 
activation in response to the thapsigargin treatment and to ensure that DMSO treatment did not 
induce PBLs activation. 
Induction of ER stress in the PBLs was achieved   by treatment with 600nM thapsigargin 
or DMSO (negative control) for 4 h. Cells were harvested, RNA isolated and RT-qPCR 
PBLs 
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RNA isolation 
RT-qPCR 
 
PBLs + 
600 nM Thapsigargin  
4 h incubation 
PBLs + 
 2 μl DMSO 
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performed. The expression of each gene after thapsigargin treatment was compared to the 
expression of the same gene in cells treated with DMSO, and expressed as fold change. The 
experiments were performed in duplicate and repeated on 4 different occasions. 
2.1.8 Statistical analysis 
UPR gene expression (as ΔCq) in thapsigargin stimulated E.Derm cells at individual time 
points was compared to UPR gene expression (as ΔCq) in DMSO treated E.Derm cells.  
Replicate values within each experiment were averaged. Data from all experiments was analyzed 
by paired T-test with a rejection level of p value > 0.05, using StataIC 10 software (StataCorp. 
2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP). For graphing 
purposes in the figures, data are expressed as the fold change of stimulated versus unstimulated 
cells. 
 
2.2 Results 
2.2.1 Primer specificity  
Primer sequences and characteristics for all genes are shown in table 2.2. E.Derm cells 
stimulated for 4h with 300 nM thapsigargin were used to validate the primers for the UPR genes 
and 18s ribosomal RNA. The size of the PCR products, estimated from agarose gels, agreed with 
the expected product sizes (Figure 2.1). The nucleotide similarities for the analyzed sequences 
(Table 2.3) were as follows: GRP78 and CHOP 99% and HERP 98% similarity without gaps; 
XBP1s 98% similarity with 1 gap. The 18s amplified PCR product agreed 100% with the 
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compared database sequence for that gene. Expression of the 18s ribosomal RNA was not 
modified by the treatments and remained stable for at least 18 h, as is shown in Figure 2.2. 
2.2.2 Primer characteristics:  
Primer efficiency: Using cDNA dilutions obtained from E.Derm cells treated with 300 
nM thapsigargin for 4 h, the following efficiency values were found to be acceptable (Figure 2.3 
A): reference gene 18s primers (105%), GRP78 gene primers(143%) and XBP1s gene primers 
(108%). On the other hand, HERP and CHOP gene primers showed efficiency values higher than 
200% (520% and 366%, respectively) and were considered not ideal. The dissociation curves for 
CHOP and HERP genes suggested that mispriming or primer-dimer artifact occurred during the 
PCR amplification (described later in this section). However, the identity of the amplification 
product for both primer sets was established after thapsigargin treatment of the cells and an 
increase of the expression of both CHOP and HERP transcripts was consistently determined. I 
concluded that even though the efficiency for these primer sets (CHOP and HERP) was not ideal, 
and accurate quantification of gene expression was not possible, the primers were specific as the 
product of amplification was identical to the expected product.  
An amplification plot depicts the fluorescence signal, an indicator of product 
concentration, at each cycle number (Figure 2.3 B). A horizontal line represents the threshold, 
and the cycle at which the fluorescence signal first exceeds the threshold is the Cq or 
quantification cycle value (this is often also referred to as the cycle threshold or Ct). A Cq is 
determined for each target. There is an inverse relationship between the Cq value and the 
quantity of product. As can be seen in Figure 2.4, treatment of E.Derm cells with thapsigargin 
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resulted in induction of gene expression for all UPR-related genes as shown by a lower Cq value 
(i.e. the curve shifts to the left) when compared to the Cq value in DMSO-treated control cells.  
The temperature at which the two strands of a double-stranded PCR product disassociate 
is a reflection of the nucleotide sequence and length of the product. Following a RT-qPCR 
reaction, the product is heated and its fluorescence, measured at each degree rise in temperature, 
is expressed as a change in fluorescence per degree. The resulting dissociation curve provides an 
indication of the homogeneity of the product (Figure 2.3 C). Mixed products yield multiple or 
aberrant dissociation profiles. Figure 2.3 C shows the dissociation curves for PCR products for 
each gene. For 18s, XBP1s and GRP78, the dissociation curves represent homogeneous PCR 
products as each is composed of single peak. The melting curves for CHOP and HERP were 
different. It can be noted that there is a “shoulder” in the CHOP curve, before it reached the peak 
at the temperature described for that product. The melting curve for HERP also shows a 
peculiarity. There is a primary curve followed by the expected melting curve with the 
characteristic peak. This primary curve could correspond to a product different than the expected 
product. Such products are the results of mispriming, i.e.  the annealing of primers to sequences 
on non-target DNA that are partially complementary to the target DNA. Primers can also form 
primer dimer artifacts by annealing to themselves and creating small templates for PCR 
amplification. The presence of any of these structures could explain the increased apparent 
efficiency values calculated. However, as described previously, the specificity of the primers was 
confirmed as the identity of the product being amplified in the PCR reaction corresponded to the 
target genes.  
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2.2.3 UPR activation in equine dermal cells  
To examine the UPR activation over an 18-hour period, E.Derm were treated with 
thapsigargin or DMSO for 4h, and total RNA was collected for detection of UPR gene 
expression by RT-qPCR  at 4h, 8h or 18h (Figure 2.5). At each time point, the expression of each 
gene after thapsigargin treatment was compared to the expression of the same gene in cells 
treated with DMSO, and expressed as fold change.  
For the GRP78 gene, CHOP gene and HERP gene there was an increase in gene 
expression in thapsigargin-treated cells at each time point compared to DMSO treated cells). The 
fold changes for GRP78 expression at t4, t8 and t18, respectively, were: 5.957 (p=<0.0001); 
13.913 (p=0.02) and 20.710 (p=0.004). The fold changes for CHOP expression at t4, t8 and t18, 
respectively, were: 25.789 (p=<0.0001); 23.761 (p=0.019) and 26.598 (p=0.0008). The fold 
changes for HERP expression at t4, t8 and t18, respectively, were 42.459 (p=<0.0001); 30.688 
(p=0.0003) and 35.149 (p=0.008). The fold change for XBP1s gene expression at t4 was 1.768 
(p=0.278), at t8 was 3.319 (p=0.051) and at t18 was 3.265 (p=0.047) (Figure 3.5.). XBP1s gene 
expression was therefore not induced at t4, and at t8 and t18 the increase in gene expression was 
not as marked as it was for the other 3 genes. For that reason I decided to focus on the genes 
(HERP, CHOP and GRP78) that showed higher induction after treatment with thapsigargin. 
Unfortunately, efficiency for all the primer sets was not calculated until after these experiments 
were performed. Even though the efficiency for the CHOP and HERP primer sets was 
considered less than ideal, I decided to continue working with these primer sets as induction of 
gene expression after thapsigargin treatment was consistently detected and the correct PCR 
products were amplified.   
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2.2.4 UPR activation in equine peripheral blood leukocytes 
Figure 2.6 shows that the UPR genes CHOP, GRP78 and XBP1s were consistently 
induced by cell treatment with thapsigargin, presenting fold change values of 13.4 (P=0.006), 
31.1 (P=0.004) and 13.7 (P=0.01), respectively. The expression of HERP was not induced in 
PBLs by thapsigargin treatment (fold change value 0.09, p=0.60). Expression of the TNFα gene 
was induced by thapsigargin treatment presenting a fold change value of 41.8 (p=0.01). I 
concluded that the UPR was activated by the use of thapsigargin, although the profile of the 
genes being induced did not follow the same pattern as in E.Derm cells: HERP expression was 
not induced in PBLs while XBP1s expression was induced in PBLs. This may be a consequence 
of the different nature of the cells. 
 
2.3 Discussion 
To study UPR activation in equine cells, primers were designed and tested in equine 
dermal cells (E.Derm) treated with thapsigargin, a chemical compound that produces a calcium 
imbalance in the cells and induces ER stress. Expression of the 18s gene remained stable for the 
full 18h of the experiment and was not affected by thapsigargin treatment, which confirmed that 
it was a useful reference gene for the gene expression experiments. The primers that were 
designed to identify the expression of the UPR genes HERP, CHOP, GRP78 and XBP1s were 
confirmed to amplify the correct targets in E.Derm cells. Although primer characteristics were 
not ideal for all the primers, the RT-qPCR assay was considered to be sufficiently useful for use 
in further experiments. Mispriming or primer dimer artifacts may have occurred when using the 
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CHOP and HERP primers, however, this did not interfere with amplification of the correct 
product. 
I concluded that the primers correctly amplified horse UPR gene transcripts and that the 
UPR in equine cells was activated by the use of thapsigargin. This is the first report addressing 
UPR activation in cells of equine origin. The UPR remained activated in E.Derm cells for an 18-
hour period, evaluated at 3 different time points, after thapsigargin treatment. The profile of the 
genes induced in PBLs was not the same as in E.Derm cells: HERP expression was induced in 
E.Derm cells but not in PBLs, and conversely, XBP1s expression was induced in PBLs but not in 
E.Derm cells. This difference in gene expression between the E.Derm and PBLs was not 
expected and may be a consequence of the different nature of the cells. Dermal cells are cells 
with higher metabolic activity compared to PBLs, and it is possible that some cellular pathways 
related to the UPR present different activation profiles in these 2 cell types.  
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Table 2.1 Selected UPR genes: names, abbreviations and NCBI accession numbers.   
Name NCBI Accession number 
Equus caballus similar to X-box binding 
protein 1 isoform XBP1s 
(LOC100059209), mRNA XM_001916129 
 
Equus caballus 78 kDa glucose-regulated 
protein-like GRP78   
(LOC100067235),  miscRNA XR_131575.1 
 
Equus caballus DNA damage-inducible 
transcript 3 protein-like CHOP 
(LOC100053417), mRNA XM_001488999.1 
 
Equus caballus homocysteine-responsive 
endoplasmic reticulum-resident ubiquitin-like 
domain member 2 protein-like HERP 
(LOC100055464), mRNA XR_036041.3 
 
Equus caballus 18S ribosomal RNA (18s) gene AJ311673.1 
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Table 2.2 Details of primer pairs as obtained from the Primer3 (v.0.4.0) software 
 
       18S  rRNA Sequence (5'->3') Template strand1 Length2 Start3 Stop4 Tm5 GC%6 
Forward primer 
 
AAACGGCTACCACATCCAA Plus 19 426 444 58.99 47.37 
Reverse primer 
 
TCGGGAGTGGGTAATTTGC Minus 19 479 461 60.85 52.63 
Product length7 54  
 
       HERP Sequence (5'->3') Template strand Length Start Stop Tm GC% 
Forward primer CCGAGCCTGAGCCCGTCACG Plus 20 102 121 67.61 75.00 
Reverse primer CTTTGGAAGCAAGTCCTTGA Minus 20 313 294 55.87 45.00 
Product length 212  
 
       CHOP Sequence (5'->3') Template strand Length Start Stop Tm GC% 
Forward primer TGGAAGCCTGGTATGAGGAC Plus 20 149 168 58.80 55.00 
Reverse primer TGCCACTTTCCTCTCGTTCT Minus 20 489 470 58.95 50.00 
Product length 341  
 
 
XBP1 s 
 
Sequence (5'->3') 
 
Template strand 
 
Length 
 
Start 
 
Stop 
 
Tm 
 
GC% 
 
Forward primer 
 
GCGGGTCTGCTGAGTCTGCAGC 
 
Plus 
 
22 
 
486 
 
507 
 
71.13 
 
68.18 
 
Reverse primer 
 
GGGTGCTTCCTCAATTTTC 
 
Minus 
 
19 
 
867 
 
849 
 
57.16 
 
47.37 
 
Product length 
 
383  
 
 
       GRP78 
 
Sequence (5'->3') 
 
Template strand 
 
Length 
 
Start 
 
Stop 
 
Tm 
 
GC% 
 
Forward primer 
 
GGCTTGGATAAGAGGGAAGG 
 
Plus 
 
20 
 
844 
 
863 
 
57.35 
 
55.00 
 
Reverse primer 
 
GGTAGAACGGAACAGGTCCA 
 
Minus 
 
20 
 
1230 
 
1211 
 
59.03 
 
55.00 
 
Product length 
 
387  
                                                 
 
1
 Refers to the direction of the RNA strand to which the primer anneals 
2
 Primer length (in bp) 
3
 Nucleotide position where the primer starts 
4
 Nucleotide position where the primer stops 
5
 Melting temperature (in °C) of the primer, the temperature at which the primer disassociates from the template. 
6
 Guanine-cytosine content of the primer (in percent) 
7
 Product length (in bp) 
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Table 2.3 Sequence alignments between the RT-qPCR amplification products (top) and the 
published equine mRNA sequences (bottom). Percentage of identity and percentage or number 
of gaps is indicated. The black arrow shows a gap; bold underlined letters show mismatches. 
GRP78 
 
Identities = 343/345 (99%), Gaps = 0/345 (0%) 
 
GRP78             16      CGAGTCAGGGTCTCAGAGAAGTCTTCTCCTTCATAGAAGGATTCAATTTCAATTCTTGCT  75 
XR_131575.1  1277  CGAGTCAGGGTCTCAGAGAAGTCTTCTCCTTCATAGAAGGATTCAATTTCAATTCTTGCT  1218 
 
GRP78              76     TGATGTTGAGAAGACAGGGCCCGTTTGGCCTTTTCTACCTCACGCCGGAGTTTCTGCACA  135 
XR_131575.1  1217  TGATGTTGAGAAGACAGGGCCCGTTTGGCCTTTTCTACCTCACGCCGGAGTTTCTGCACA  1158 
 
GRP78              136    GCTCTGTTGTCTTTCCGAACATCTTTGCCAGTCTTCTTTTTGTAGAGCTTGATGAAGTGT  195 
XR_131575.1   1157  GCTCTGTTGTCTTTCCGAACATCTTTGCCAGTCTTCTTTTTGTAGAGCTTGATGAAGTGT  1098 
 
GRP78              196    TCCATGACACGCTGGTCGAAGTCTTCTCCCCCCAGATGAGTATCTCCATTAGTGGCCACA  255 
XR_131575.1   1097  TCCATGACACGCTGGTCGAAGTCTTCTCCCCCCAGATGAGTATCTCCATTAGTGGCCACA  1038 
 
GRP78               256   ACTTCGAAGACACCATTATCAATGGTGAGAAGAGACACATCGAAGGTTCCACCACCCAGG  315 
XR_131575.1   1037  ACTTCGAAGACACCATTATCAATGGTGAGAAGAGACACATCGAAGGTTCCACCACCCAGG  978 
 
GRP78               316   TCAAACACCAGGATGTTCTTCTCCCCTTCCCTCTAATCCAAGCCA  360 
XR_131575.1    977   TCAAACACCAGGATGTTCTTCTCCCCTTCCCTCTTATCCAGGCCA  933 
 
 
 
CHOP 
 
Identities = 297/298 (99%), Gaps = 0/298 (0%) 
 
CHOP                      17    CGTTGCTTTTCAGCCCGGGCTGGGGACTGGCCACTCTGTTTCCGTTTCCTAGGTCTTACT  76 
XM_001488999.1   353  CGTTGCTTTCCAGCCCGGGCTGGGGACTGGCCACTCTGTTTCCGTTTCCTAGGTCTTACT  294 
 
CHOP                      77    TGGTCTTCCTCTTCTTCCTCCTGAGCCAGGGAGCTCTGACTGGAATCTGGAGAGCGAGGG  136 
XM_001488999.1   293  TGGTCTTCCTCTTCTTCCTCCTGAGCCAGGGAGCTCTGACTGGAATCTGGAGAGCGAGGG  234 
  
CHOP                      137  CTCTGGGAGGTGCTCGTGACCTCTGCTGGCCCTGGTTCCTCGGTCAGCCACGCCAGAGAG  196 
XM_001488999.1   233  CTCTGGGAGGTGCTCGTGACCTCTGCTGGCCCTGGTTCCTCGGTCAGCCACGCCAGAGAG  174 
 
CHOP                      197   GCGGGGTCAAGAGTGGTGAAGGTTTTTGATTCTTCCTCCTCGTTTCCAGGGGGTGAGACA  256 
XM_001488999.1   173   GCGGGGTCAAGAGTGGTGAAGGTTTTTGATTCTTCCTCCTCGTTTCCAGGGGGTGAGACA  114 
 
CHOP                      257   TAGGTACCCCCATTTTCATCTGAGAACAGCACCTCCTGCAGGTCCTCATACCAGGCTT  314 
XM_001488999.1   113   TAGGTACCCCCATTTTCATCTGAGAACAGCACCTCCTGCAGGTCCTCATACCAGGCTT  56 
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HERP 
 
Identities 166/169(98%) Gaps 0/169(0%) 
 
HERP                14   GCGCCACCGCGACTTGGAGCTGAGCGGCGACCGCAGCTGGAGCGTGGGCCGCCTCAAGGC  73      
XR_036041.3   201  GCGCCACCGCGACTTGGAGCTGAGCGGCGACCGCAGCTGTAGCGTGGGCCGCCTCAAGGC  260 
 
HERP                74    TCATCTGAGCCGCGTCTACCCCGAGCGCCCGCGGCCGGAGGACCAGAGGTTAATTTATTC  133 
XR_036041.3   261  TCATCTGAGCCGCGTCTACCCCGAGCGCCCGCGGCCGGAGGACCAGAGGTTAATTTATTC  320 
 
HERP               134   CGGGAAGCTCTTGTTGGATCACCAGTGTCTCAAGGACTTGCTTCCAAAG  182 
XR_036041.3   321  CGGGAAGCTCTTGTTGGATCACCAGTGTCTCAGGGACTTGCTCCCAAAG  369 
 
XBP1s 
Identities = 371/377 (98%), Gaps = 1/377 (0%) 
 
XBP1s                     7      CTTGACTCTCTGTCT-AGAGGGTATCTCTAAGACTAGGGGTTTGGTATATACGTGGTCAA  65 
XM_001916129.2  886  CTTGGCTCTCTGTCTCAGAGGGTATCTCTAAGACTAGGGGTTTGGTATATACGTGGTCAA  827 
 
XBP1s                     66   AACGAATCAGTTCATTAATGGCTTCCAGCTTGGCTGATGACGTCCCCAGTGATGGAGAAG  125 
XM_001916129.2  826  AACGAATCAGTTCATTAATGGCTTCCAGCTTGGCTGATGACGTCCCCAGTGATGGAGAAG  767 
 
XBP1s                     126  GGGAGGCTGGTAAGGAACTGGGTCCTTCTGGGTAGACCTCTGGGAGTTGCTCCAGGCTGG  185 
XM_001916129.2  766   GGGAGGCTGGTAAGGAACTGGGTCCTTCTGGGTAGACCTCTGGGAGTTGCTCCAGGCTGG  707 
 
XBP1s                     186  TCGATTCTGGGGAAGGACATCTGAAGAACATGACTGGGTCCAAGTTGAACAGAATGCCCA  245 
XM_001916129.2  706  TCGATTCTGGGGAAGGACATCTGAAGAACATGACTGGGTCCAAGTTGAACAGAATGCCCA  647 
 
XBP1s                     246  ACAGGATATCAGACTCAGAGTCTGAAGAGTCCACACTGTCAGAATCCATGGGGAGAGGTT  305 
XM_001916129.2  646  ACAGGATATCAGACTCAGAGTCTGAAGAGTCCACACTGTCAGAATCCATGGGGAGAGGTT  587 
 
XBP1s                     306  CTGGAGGGGTGACAACTGGGCCTGCACCTGCTGCAGAGGCGCACGTACCCCGAGTGCTGC  365 
XM_001916129.2  586  CTGGAGGGGTGACAACTGGGCCTGCACCTGCTGCAGAGGCGCACGTAGACTGAGTGCTGC  527 
  
XBP1s                     366  AGACTCAGCAGACCCGC  382 
XM_001916129.2  526  GGACTCAGCAGACCCGC  510 
 
 
18s 
 
Identities = 54/54(100%), Gaps = 0/54(0%) 
 
18s                  1      AAACGGCTACCACATCCAAGGAAGGCAGCAGGCGCGCAAATTACCCACTCCCGA  54 
AJ311673.1  426    AAACGGCTACCACATCCAAGGAAGGCAGCAGGCGCGCAAATTACCCACTCCCGA 479 
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Table 2.4 Primer set for amplification of equine TNFα. 
 
  
TNFα Sequence (5'->3') Template strand Length Start Stop Tm GC% 
Forward primer AAAGGACATCATGAGCACTGAAAG Plus 24 26 49 59.54 41.67 
Reverse primer GGGCCCCCTGCCTTCT Minus 16 106 91 60.69 75.00 
Product length 81 bp 
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Figure 2.1 Expression of 18s over an 18 hour period after thapsigargin treatment. RT-qPCR 
was performed on E.Derm cells treated for 4 h with thapsigargin. Cells were harvested and RNA 
isolated at 0, 4, 8 and 18 h. Time 0 is the time when treatment was started. Time 4 is the time 
when treatment was removed. Cq values at each time point represent averages from 4 
experiments, and standard error bars are presented.  
 
             
Figure 2.2 PCR product identification. A) Table showing expected sizes of RT-qPCR products 
XBP1s, HERP, CHOP, GRP78 and 18s. B) Agarose gel electrophoresis of RT-qPCR purified 
products and 1Kb ladder marker (bp). 
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Figure 2.3 UPR primer and product characteristics. A) Calibration curves for each primer 
set. Amplification results for serial 4-fold dilutions of E.Derm cDNA were plotted as Cq values 
versus Log [dilution]. The trendline, the equation of the curve, the slope of the curve, the R 
squared value (R
2
) and the efficiency (E), in percent, are presented. B) Amplification plot curves 
for each primer set. A sigmoid curve represents the plotting of the fluorescence signal versus the 
cycle number. There is an inverse correlation between the Cq value and the quantity of product. 
C) Dissociation curves for each primer set. The fluorescence signal emitted by dissociating 
double stranded cDNA is plotted as a function of rising temperature. Figures are from one 
representative experiment.  
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Figure 2.4 Amplification plots and dissociation curves for GRP78, CHOP, HERP and 
XBP1s. Blue lines represent thapsigargin treated E.Derm samples. Red lines represent DMSO 
treated control samples. A) Amplification plots. Thapsigargin treated samples (blue lines) shift to 
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the left with respect to DMSO treated samples (red lines) as transcripts for that gene increase in 
the sample and correspondingly, Cq values decrease. Black arrows indicate the Cq value as the 
point where the curve crosses the horizontal threshold (black line) B) Dissociation curves 
showing melting characteristics of the PCR products. Note that the red curves for CHOP and 
HERP follow the same pattern as the blue curves. The difference in height may be due to the 
quantity of product present in DMSO treated samples (red line), which is less than that in 
thapsigargin treated samples (blue line). Figures are from one representative experiment. 
 
 
Figure 2.5  Expression of UPR genes in E.Derm cells after thapsigargin treatment. E.Derm 
cells were treated with 600 nM of thapsigargin or with 2 μl of DMSO (control). At t4, t8 and t18 
(hours after treatment was added), cells were harvested, cellular RNA was isolated, and RT-
qPCR was performed. Gene expression was calculated as fold change (see materials and 
methods) of thapsigargin treated cells versus DMSO treated cells. Error bars represent standard 
error, n=9. * p<0.05 
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Figure 2.6 Expression of UPR genes and TNF alpha in PBLs after thapsigargin treatment. 
PBLs were isolated from a whole blood sample and treated for 4 h with 600 nM of thapsigargin 
or with 2 μl of DMSO as a control. After 4 h, PBLs RNA was isolated and RT-qPCR performed. 
Gene expression was calculated as fold change (see materials and methods) of thapsigargin 
treated cells versus DMSO treated cells. n=4 Error bars represent standard error. * p<0.05  
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3 LYTIC EHV-1 INFECTION IN EQUINE CELLS 
The second objective of this project was to characterize lytic EHV-1 infection in equine 
dermal cells and detect the expression of EHV-1 genes over time. Toward the first goal, E.Derm 
cells were inoculated with EHV-1 and viral replication was assessed by visual inspection of the 
cells and a single step growth curve was produced in order to determine the dynamics of EHV-1 
replication. The replication cycle of viruses can be divided into three basic components when 
assessed by a single step growth curve: the attachment period, the eclipse period and the period 
of release of virus particles. The attachment and penetration period corresponds to the initial 
contact of the virus with the host cell. During the eclipse period, infectious virus cannot be 
detected as synthesis, assembly and maturation of virions is taking place. During the release of 
mature virions, an exponential increase in the concentration of infectious virus occurs. The 
elapsed time from the attachment period to the release of infectious mature virions is 
characteristic for each virus. I wanted to investigate the time frame of EHV-1 growth in cultured 
cells to correlate the landmarks in the replication cycle with the gene expression during lytic 
infection.  
Toward the second goal, a RT-qPCR for detection of EHV-1 genes representing the 
different temporal gene classes was designed, and the expression of EHV-1 genes of different 
temporal classes was determined over an 18-hour time period following infection of E.Derm 
cells. The process of reactivation from latency is thought to resemble the lytic cycle, as both 
processes require expression of lytic viral proteins. The molecular events involved in the 
establishment, maintenance and reactivation from latency for EHV-1 have not been elucidated, 
but in order to understand them, it is first necessary to comprehend the molecular events during 
the lytic cycle. Since there are relatively little comparative data on the regulation of viral gene 
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expression during the lytic cycle of EHV-1, I examined viral gene expression during EHV-1 
infection of equine dermal cells (E.Derm). The experiments were also intended to confirm that I 
could reliably detect lytic EHV-1 infection by CPE detection and by viral gene expression in 
culture. 
EHV-1 genes can be classified as Immediate Early (IE), Early (E) or Late (L) genes based 
on the order of their expression. Genes representing each temporal class were selected: the 
immediate early gene from the IE class, the ICP0 gene from the E class, and the gB and E-VP16 
genes from the L class (Gray, Baumann et al. 1987). During lytic EHV-1 infection, transcripts of 
the IE gene and some E genes can be detected starting at 4 h post infection (HPI) while the late 
genes can be detected as late as 18 HPI (Caughman, Staczek et al. 1985; Gray, Baumann et al. 
1987). For the gene expression experiments described here, time points were therefore selected 
to represent the early events before infectious virus is detected (t4), the beginning of infectious 
virus detection (t8) and the advanced cell infection (t18, see diagram in materials and methods). 
Cells were also harvested immediately upon removal of viral inocula (t0) for comparison to 
uninfected cells.  
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3.1 Materials and methods 
3.1.1 Equine dermal cell culture  
 E.Derm cells were cultured as described in chapter 2. 
3.1.2 Virus  
A neuropathogenic (D752) field isolate of EHV-1 was obtained from Prairie Diagnostic 
Services Inc. (PDS, Saskatoon, Saskatchewan, Canada). The virus was isolated from an affected 
horse during a 2008 EHM outbreak in Saskatoon and confirmed to be a neuropathogenic strain 
of EHV-1 by PCR testing (Animal Health Laboratory, University of Guelph, ON). Virus stock 
was originally grown in Vero cells and viral DNA was purified. Subsequent viral stocks were 
propagated in E.Derm cells. Briefly, E.Derm cells were washed once with DMEM without serum 
and virus, diluted 1:25 in DMEM without serum, was added. Cells with viral inocula were 
incubated for 1 h at 37°C. Complete DMEM was added to each flask and cells returned to the 
incubator at 37°C until CPE was detected.  
For the plaque assay to determine virus titers (see below) serum containing neutralizing 
antibodies from one client-owned horse (an Arabian gelding, 22 years of age, that tested positive 
to EHV-1 during an EHM outbreak, referred as horse 2 in section 5.1.1) was used; a serum 
neutralization test was performed to determine levels of anti-EHV-1 antibodies in the serum.  
Forty thousand E.Derm cells were plated per well in a 24 well plate. One thousand plaque 
forming units (pfu) of EHV-1 were incubated with serial five-fold dilutions of the serum for 1 
hour at 37°C before addition to each well containing E.Derm cells. Following incubation for 24 h 
at 37°C in a 5% CO2 humidified atmosphere, plates were observed for cytopathic effect (CPE) to 
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determine the serum dilution that neutralizes viral growth. The neutralizing antibody titer was 
determined as the inverse of the highest dilution at which no plaques were detected. The 
neutralizing titer was 5, corresponding to the dilution 1:5.   
Virus titers were determined by plaque assay as follows:  E.Derm cells were plated in 24 
well plates at 1x10
5
 cells per well. Five hundred μl of serially diluted virus (10-2 to 10-7) were 
added and cells incubated for 1 h at 37°C while plates were swayed every 15 minutes. Inocula 
were removed from wells and replaced with DMEM containing EHV-1 neutralizing antibody 
serum (see above). Plates were incubated at 37°C for 4 days until plaques were visible. Medium 
was removed; cells were fixed in methanol and stained with Giemsa stain (BDH Inc.) to 
visualize and count plaques. Giemsa stain was prepared as a 0.8% dilution of Giemsa powder in 
equal parts of methanol and glycerol. Plaques per well were counted and virus concentration 
calculated using the following formula: 
# of plaques per well 
=  pfu/ml 
d x V 
Where d= dilution factor and V= volume of diluted virus added to each well. 
3.1.3 Lytic EHV-1 infection in equine dermal cells 
E.Derm cells (1x10
6
/well) were plated in 6 well plates and inoculated with EHV-1 at a 
multiplicity of infection (moi) = 0.01pfu/cell. The low moi allowed me to observe the infected 
culture as the virus spread from cell to cell. Two 6 well plates were inoculated and maintained 
for 6 days. The cultures were visually examined and photographed every day for characteristic 
alphaherpesvirus cytopathic effect (CPE). This CPE is characterized by focal rounding up of 
cells followed by an increase in refractility and detachment from the cell monolayer.  
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3.1.4 Single step growth curve 
E.Derm cells were plated (1x10
5 
cells/well) in 6 well plates and inoculated with EHV-1 at 
a moi of 1pfu/cell. After one hour of incubation at 37°C (5% CO2) to allow for virus attachment, 
the inocula were removed, fresh media was added and cells return to the incubator. Time 0 (t0) 
was defined as the time when inocula were removed and fresh media was added to the wells. 
Cells were harvested at t0, t4, t8, t12, t24 and t36. Plaque assays were conducted to determine the 
number of pfu per cell associated with the cultures at different times after infection. The 
experiment was performed in duplicate and repeated on 3 different occasions. 
3.1.5 Polymerase chain reaction (PCR) 
PCR reactions, purification of PCR products and sequencing were performed as 
described in chapter 2. Purified EHV-1 DNA from our viral stock was used to determine the 
specificity of the primers by RT-qPCR. EHV-1 DNA was isolated as described previously (Gray, 
Baumann et al. 1987). Viral genes were selected to represent the three classes of IE, E and L 
genes and GenBank accession numbers for the selected genes are shown in table 3.1.  Primers for 
equine glycoprotein B and E-VP16 transcripts were designed as described in chapter 2 while 
primers for IE and ICPO transcripts were as described previously (Hasebe, Kimura et al. 2006). 
Characteristics of the latter two primer pairs were corroborated with the Primer 3 software. Gene 
expression at each time point was normalized to the 18s ribosomal RNA. By convention, RT-
qPCR data is expressed as fold changes compared to control. For example, a sample treated with 
a drug may have 5 fold more RNA for a particular gene when compared to an untreated sample. 
For cells infected with a virus, this type of comparison is not possible since the obvious control – 
mock-infected cells – would contain no viral transcripts and would therefore have no Cq values 
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for any of the viral gene products. Viral gene expression at individual time points was therefore 
quantified with respect to gene expression at the time of infection (t0), i.e. the normalized value 
for a gene (∆Cq) at t0, when only background levels of transcripts would be present, was 
subtracted from the normalized value at each  time point after infection. Gene expression was 
then reported as the minus maximum ∆Cq value versus time zero. It should be noted that 
herpesviruses have the ability to shut down translation of cellular host mRNA and also have the 
ability to degrade mRNA. In contrast, levels of 18s ribosomal RNA remain constant (Figure 3.5 
B) after herpesvirus infection (Nishioka and Silverstein 1977).  
3.1.6 Expression of EHV-1 genes during lytic infection in E.Derm cells 
Experimental design diagram: 
 
 
 
 
 
E.Derm cells were plated (2x10
5
cells/well) in 6 well plates and inoculated with EHV-1 at 
a moi of 5 pfu/cell (t -1). A relatively high moi was used to increase the probability of 
simultaneous infection of all cells in the culture. After one hour of incubation at 37⁰C, the 
inoculum was removed, fresh media was added and cells were returned to the incubator. Cells 
were harvested immediately after fresh media was added (t0), and at t4, t8 and t18 (see diagram). 
RNA was extracted as described in chapter 2 and EHV-1 gene expression was analyzed using 
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RT-qPCR. As a precaution, a DNAse treatment step was added during RNA extraction to assure 
that viral DNA was not amplified during the PCR reaction. Absence of DNA was confirmed by 
performing a qPCR without previous synthesis of cDNA in the sample.  The experiment was 
performed in duplicate and repeated on 7 different occasions.  
 
3.2 Results 
3.2.1 Lytic EHV-1 infection in equine dermal cells 
One day post inoculation CPE were detected in all wells. By day 6, almost 80% of all cells 
showed CPE. Figure 3.1 shows images representative of days after inoculation. 
3.2.2 Single step growth curve 
 The growth of EHV-1 in E.Derm cells resembled that described previously (Hussey, 
Hussey et al. 2011). It should be noted that the virus concentration in Figure 3.9 at t0 represents 
the input virus concentration of 1 pfu/cell. No virus could be detected t4, corresponding to the 
eclipse period in virus replication (Dubovi and Maclachlan 2011). After the eclipse period, viral 
pfu increased between t8 and t12 from 3.35 x 10
-3
 to 0.6 pfu/cell. Viral production at t24  
corresponded  to 1.5 pfu/cell, approaching a maximum plateau level of 16 pfu/cell at t36. These 
values represent relatively poor yields of virus and suggest that although cells showed cytopathic 
effect relatively few infected cells produced infectious virus. Increase in the infectious virus 
concentration was detected from t8 and by t12, the lytic cycle was completed. 
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3.2.3 Primer specificity 
The primer pairs used for detection of EHV-1 gene transcripts are detailed in Table 3.2. 
QPCR was performed on purified EHV-1 DNA and the product sizes estimated by gel 
electrophoresis matched the expected sizes (Figure 3.3). PCR product were sent for sequencing 
and the nucleotide sequences for the ICP0, IE, E-VP16 and gB amplified PCR products agreed 
100% with the compared database sequence for each gene without gaps (Table 3.3). 
3.2.4 Primer characteristics 
Using serial 4 fold dilutions of viral DNA for each gene, the following efficiency values 
were found to be acceptable (Figure 3.4 A): the ICP0 gene primer set showed an efficiency of 
112%; the E-VP16 gene primer set showed an effciency of 127%; the gB gene primer set showed 
an efficiency of 115% and the IE gene primer set showed an efficiency of 87%. The 
amplification plots and dissociation curves generated by the qPCR software for each gene are 
shown in Figure 3.4 B and C. The PCR products’ characteristics suggested the correct identity 
for all the amplified targets.   
3.2.5 Expression of EHV-1 genes during lytic infection in E.Derm cells 
 As shown in Figure 3.5 A, transcripts for the immediate early and early class of genes (IE 
and ICP0, respectively) were present at relatively higher levels at t4 than those for the late genes 
(E-VP16 and gB). However, transcripts for all genes continued to increase and expression of the 
IE, E and L genes was more similar at t8 and t18.  
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3.3 Discussion 
Lytic EHV-1 infection in equine cells was detected by observation of CPE, infectious 
virus was detected at t8 and by t12 the replication cycle was complete. The growth of EHV-1 in 
E.Derm cells resembled that described previously (Hussey, Hussey et al. 2011). 
EHV-1 gene expression was determined by RT-qPCR. Primers were designed and tested 
by qPCR in EHV-1 purified DNA. The primers that were designed to identify the EHV-1 genes 
IE, ICP0, E-VP16 and gB were confirmed to amplify the correct target in infected E.Derm cells 
by RT-qPCR. The expression of EHV-1 genes in E. Derm cells was assessed over the 18 h 
following an hour of incubation with the virus and replacement of media. At t4, expression of the 
IE and E genes was relatively higher than the expression of the L genes while this discrepancy 
disappeared at t8 and t18. The increased expression of all gene classes simultaneously can be 
explained because in culture, we can find infected cells that are at the first stages of infection 
expressing the IE gene and other cells that are in a later stage of infection expressing the E or the 
L genes in the same well. These findings do not represent a different temporal pattern of viral 
gene expression; it is a consequence of the experiment itself.   
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Table 3.1 Selected EHV-1 genes: names, abbreviations, NCBI accession numbers and gene 
classification.   
Name NCBI Accession number Gene class 
Equine herpesvirus type 1 immediate-
early protein gene, IE 
J04366.1 Immediate early α 
Equine herpesvirus 1 ORF63 gene for 
transactivator protein, (homologue of 
HSV ICP0) ICPO 
AB158517.1 Early β 
Transactivating tegument protein, Equid 
herpesvirus 1 ORF12 (homologue of 
HSV VP16) E-VP16 
YP_053057.2  
NC_001491.2 From 13595 to 
14953 
Late γ1 
Equid herpesvirus 1 ORF33 gene for 
glycoprotein B (homologue of HSV 
glycoprotein B) gB 
AB279609.1 Late γ2 
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Table 3.2 Details of primer pairs as obtained from the Primer3 (v.0.4.0) software.  
 
     IE Sequence (5'->3') Template strand1 Length2 Start3 Stop4 Tm5 GC%6 
Forward primer CGACAGCGATACCGAGACCT Plus 20 1434 1453 61.44 60.00 
Reverse primer TTCGTCGCTGTCGCTGTCGT Minus 20 1647 1628 64.77 60.00 
Product length7 214  
     
     E-VP16 Sequence (5'->3') Template strand Length Start Stop Tm GC% 
Forward primer CGGGGTAGTGATCTTGGAAA Plus 20 14446 14465 56.93 50.00 
Reverse primer TCGGTCGTTGTACCGTATGA Minus 20 14751 14732 58.55 50.00 
Product length 306  
 
 
     ICPO Sequence (5'->3') Template strand Length Start Stop Tm GC% 
Forward primer TTTTTGGCCGTGGATTCTGG Plus 20 259 278 59.03 50.00 
Reverse primer AGTTCTGCTTGGACGATGAG Minus 20 566 547 57.62 50.00 
Product length 308  
 
  Glycoprotein B Sequence (5'->3') Template strand Length Start Stop Tm GC% 
Forward primer GGCAGACCACCAACGATACT Plus 20 812 831 59.75 55.00 
Reverse primer CGACTTTCTTCTCGGTCCAG  Minus 20 1159 1140 58.02 55.00 
Product length 348  
 
 
                                                 
1
 Refers to the direction of the RNA strand to which the primer anneals  
2
 Primer length in bp 
3
 Nucleotide position where the primer starts 
4
 Nucleotide position where the primer stops 
5
 Melting temperature (in °C) of the primer 
6
 Guanine-cytosine content (in percent) of the primer 
7
 Product length in bp 
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Table 3.3 Sequence alignment between the RT-qPCR amplification products (top) and the 
published EHV-1 genes (bottom). Percentage of identity and percentage or number of gaps.  
ICP0 
Identities = 203/203 (100%), Gaps = 0/203 (0%) 
 
ICP0               1      CGAGTGAGCTCTTCCTCGTTACAGCCATGCTCGCACAGTGTATCCATAACAATGTTCCGC  60 
U81154.1      755   CGAGTGAGCTCTTCCTCGTTACAGCCATGCTCGCACAGTGTATCCATAACAATGTTCCGC  696 
 
ICP0              61   ATCACCAACGCTAGCTCTGGGGTCTCGAATAGCTGGTCGAGCCTTTCGACCAGCCAGTCC  120 
U81154.1     695  ATCACCAACGCTAGCTCTGGGGTCTCGAATAGCTGGTCGAGCCTTTCGACCAGCCAGTCC  636 
 
ICP0              121 ACCAGTGGCTGCAGTCGGGGAGCCCCGGCAGTCCCATTAGCGTTGAGGGGCACAAATGCC  180 
U81154.1     635  ACCAGTGGCTGCAGTCGGGGAGCCCCGGCAGTCCCATTAGCGTTGAGGGGCACAAATGCC  576 
 
ICP0              181 ATGGGTCCGTTCCACGCAGAGAT  203 
U81154.1     575  ATGGGTCCGTTCCACGCAGAGAT  553 
 
IE 
Identities = 162/162 (100%), Gaps = 0/162 (0%) 
 
IE                  1        CCCCGGCACCATCCGCCTGGTCGTCCTCGTCCATCGAGGACGAGGACGAGGACGACGATG  60 
J04366.1      1600   CCCCGGCACCATCCGCCTGGTCGTCCTCGTCCATCGAGGACGAGGACGAGGACGACGATG  1541 
 
IE                  61     AGATGGAGATGCTCCGGACCCGGGGTGCCGGGGACCCTCCGCCCGGGGAGGCCGAGGATG  120 
J04366.1      1540  AGATGGAGATGCTCCGGACCCGGGGTGCCGGGGACCCTCCGCCCGGGGAGGCCGAGGATG  1481 
 
IE                  121   GAAACTCGGGCTGCGGGGACCCCGGGCAGGTCTCGGTATCGC  162 
J04366.1      1480  GAAACTCGGGCTGCGGGGACCCCGGGCAGGTCTCGGTATCGC  1439 
 
E-VP16 
Identities = 295/295 (100%), Gaps = 0/295 (0%) 
 
E-VP16              1        ACCGTATGACAGGCGTCCCCCTATCCGTTTACTGTAGGAGTGCTCCGCCAGAGGAAAGAG  60 
AY665713.1    14740  ACCGTATGACAGGCGTCCCCCTATCCGTTTACTGTAGGAGTGCTCCGCCAGAGGAAAGAG  14681 
 
E-VP16             61       CGGGGTCGCCGGGTGCGCGTCCGAGTATGCCTCCATTTTGGTTCTTATCTGGTGCGTCAG  120 
AY665713.1    14680  CGGGGTCGCCGGGTGCGCGTCCGAGTATGCCTCCATTTTGGTTCTTATCTGGTGCGTCAG  14621 
 
E-VP16             121     AAAGCCAATAGTCCTGGGTAGCTTTCCCGAAAACAGAGGCTCAGCCTCGAGGGGGCTGTT  180 
AY665713.1    14620  AAAGCCAATAGTCCTGGGTAGCTTTCCCGAAAACAGAGGCTCAGCCTCGAGGGGGCTGTT  14561 
 
E-VP16             181     TTCTTCCTCGATGAGACCAGCGCGAATCAACGGTAGGCCAAGCTCGCGTCGGCGATAGTT  240 
AY665713.1    14560  TTCTTCCTCGATGAGACCAGCGCGAATCAACGGTAGGCCAAGCTCGCGTCGGCGATAGTT  14501 
 
E-VP16             241     TATCCGCTGTAGATCGTGGAACTCTAGGGGGTCGTTTTCCAAGATCACTACCCCG  295 
AY665713.1    14500  TATCCGCTGTAGATCGTGGAACTCTAGGGGGTCGTTTTCCAAGATCACTACCCCG  14446 
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gB 
Identities = 304/304 (100%), Gaps = 0/304 (0%) 
 
gB                     1        GTTCCAGCTGACGGTGACATGCGGGGTAGTGATAAAATTTTTGGTAACCGGCTCTTCGGC  60 
AB279609.1     1140  GTTCCAGCTGACGGTGACATGCGGGGTAGTGATAAAATTTTTGGTAACCGGCTCTTCGGC  1081 
 
gB                     61      TTGTAGTTTACTGTCTAAGTCGCGGGGCCTGTACCCTTCAACTTGCCTGAAACGCTCCTG  120 
AB279609.1     1080  TTGTAGTTTACTGTCTAAGTCGCGGGGCCTGTACCCTTCAACTTGCCTGAAACGCTCCTG  1021 
 
gB                      121    CGCGTAGCTATTGTGCTCTATGCGAGCGGCAGCCCTCAGGCCGTAAAACGGAGACGCGTA  180 
AB279609.1      1020  CGCGTAGCTATTGTGCTCTATGCGAGCGGCAGCCCTCAGGCCGTAAAACGGAGACGCGTA  961 
 
gB                      181    CACAATATCACCGGTGGACAGGGCGAAGGAGTCGTAGGGGTAGACGGACCGCGCCTCCAC  240 
AB279609.1      960    CACAATATCACCGGTGGACAGGGCGAAGGAGTCGTAGGGGTAGACGGACCGCGCCTCCAC  901 
 
gB                      241    CTCCTCGACGATGCAGTTGACAGACGTTGACGTGTAGTGCCTCCATGGCATCCACCCCAC  300 
AB279609.1      900    CTCCTCGACGATGCAGTTGACAGACGTTGACGTGTAGTGCCTCCATGGCATCCACCCCAC  841 
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Figure 3.1 E.Derm cells infection with EHV-1 neuropathogenic strain. Photographs (10X 
magnification) were taken daily after infection. Day 1: Normal E.Derm cells. Day 2: CPE in cells 
are detectable (Arrow heads showing CPE as examples). Day 3: Increase in the number of CPE 
Day 1  Day 2  
  
Day 3 Day 4 
  
Day 4b Day 6 
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and small areas of infected cells are visible. Day 4: further increase in the number of CPE and 
enlarged areas of infected cells. 4b) same as 4a with 20X magnification. Note the rounding up of 
the infected cells and increase in refractility. Day 6: almost 80% of E.Derm cells show CPE.  
 
 
 
 
Figure 3.2 Single step growth curve of EHV-1.  A single step growth curve was performed. 
Virus content was measured in E.Derm cells after infection with a moi of 1 pfu/cell. The virus 
titer at each time point was determined by plaque assay in E.Derm cells at t0, t4, t8, t12, t24 and 
t36 after the inoculum was removed and media replaced. The virus concentration at t0 (1pfu/cell) 
represents the input virus. At t4, no virus could be detected corresponding with the eclipse 
period. At t8, infectious virus could be detected. By t12, the replication cycle was complete.   
Error bars represent standard error n=3.  
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Figure 3.3 PCR product identification. A) Table showing expected sizes of PCR products IE, 
ICP0, E-VP16 and gB. B) Agarose gel electrophoresis of qPCR purified products and 1Kb ladder 
marker. Labeling for the ladder marker size is in bp. 
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IE 214 
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Figure 3.4 Characteristics of EHV-1 primers and products. A) Calibration curves from one 
experiment for each primer set. Serial 4-fold dilutions of DNA were plotted as Cq values versus 
Log [dilution]. The trend line, the equation of the curve, the slope of the curve, the R squared 
y = -3.065x + 9.379 
R² = 0.9558 
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value (R
2
) and the efficiency (E) in percentage, are presented. B) Amplification plot curve for 
each primer set. A sigmoid curve represents the plotting of the fluorescence signal versus the 
cycle number. There is an inverse relationship between Cq value and quantity of product. C) 
Dissociation curve for each primer set. The fluorescence signal emitted by dissociating double 
stranded cDNA is plotted as a function of rising temperature. Figures are from one representative 
experiment.  
 
    
Figure 3.5 Expression of EHV-1 genes during lytic infection in E.Derm cells. A) Following 
infection with EHV-1 at time -1h and replacement of the media at time 0 (t0), cells were 
harvested at t0, t4, t8 and t18, cellular RNA was isolated, and RT-qPCR was performed. Gene 
expression was calculated as “minus maximum ∆Cq value versus time zero”. B) Expression of 
18s over an 18 hour period. Average Cq values at each time point are shown. Error bars 
represent standard error, n=7.  
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4 INTERACTION BETWEEN EHV-1 INFECTION AND THE UPR IN 
EQUINE CELLS 
The third objective of this project was to investigate the relationship between EHV-1 
gene expression and UPR gene expression during lytic infection. 
 The tools developed in addressing the first and second objective in chapters 2 and 3 were 
used for the following: first, to determine if EHV-1 could influence expression of UPR genes 
during lytic infection and second, to evaluate if components of the UPR could influence the 
expression of EHV-1 genes of various temporal classes. In the previous chapters, I described 
how equine cells responded to thapsigargin, an inducer of the UPR, by increasing intracellular 
levels of transcripts for some UPR-related genes. The expression of EHV-1 genes in the same 
cells after viral infection was also described. Viral infection imposes ER stress by vastly 
increasing the amount of protein produced by the infected cell. In the case of enveloped viruses 
this may overwhelm the capacity of the ER for processing membrane-associated proteins (Kim, 
Xu et al. 2008), triggering activation of the UPR. This effect of virus infection on the UPR has 
been studied in different viruses including HSV-1, a member of the same subfamily as EHV-1. 
To date, no data concerning interactions between EHV-1 and the UPR in equine cells have been 
published. Prior to testing the hypothesis that activation of the UPR in latently EHV-1 infected 
peripheral blood leukocytes will trigger viral reactivation, I wanted to first determine if UPR 
activation could influence the temporal pattern of EHV-1 gene expression. Data from 
experiments with other alphaherpesviruses such as HSV (Kim, Mandarino et al. 2012) suggests 
that viral gene expression is not temporally regulated during reactivation from latency, but rather 
that all classes of genes are expressed simultaneously. A change in the EHV-1 gene expression 
during lytic infection of cells with an activated UPR would therefore support an association 
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between UPR activation and reactivation from latency. To evaluate if activation of the UPR 
influences the expression of selected EHV-1 genes during lytic infection, I examined EHV-1 
gene expression in cells in which the UPR had been activated. 
 
4.1 Materials and methods 
4.1.1 Cell cultures and reagents, virus and polymerase chain reaction (PCR) 
These were as described in chapters 2 and 3. 
4.1.2 Influence of EHV-1 infection on the UPR 
Experimental design diagram: 
 
 
 
 
To determine if lytic EHV-1 infection induced UPR activation, E.Derm cells (2x10
5
 
cells/well in 6 well plates) were inoculated with EHV-1 at a moi of 5 pfu/cell (see diagram 
below). A relatively high moi was used to increase the probability of simultaneous infection of 
all cells in the culture. After 1h of incubation at 37⁰C (5% CO2), the inoculum was removed, 
fresh media was added and cells were returned to the incubator. Cells were harvested over the 
following 18 h: immediately (t0), and at t4, t8, and t18. Expression of UPR genes (HERP, CHOP 
RNA Isolation  
RT-qPCR 
E.Derm Cells  
EHV-1 
inoculation 
    t0 t4  t8 t18 t-1 
Media replaced 
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and GRP78) was analyzed using RT-qPCR. The experiment was performed in duplicate and 
repeated on 7 different occasions. 
The reference gene 18s was used as a normalizer, as in previous experiments. Fold 
change was calculated compared to t0 samples instead of comparing to a control sample. I 
arbitrarily decided to regard 2 fold changes in gene expression (either increase or reduction) as 
biologically relevant.  
4.1.3 Influence of the UPR activation on EHV-1 gene expression  
Experiment design diagram 
 
 
 
 
 
 
E.Derm cells (2x10
5
 cells/well in 6 well plates) were first treated with either 600nM of 
thapsigargin or DMSO as control. After 4 h of treatment (t-5 to t-1, see diagram below), medium 
was removed and cells were inoculated with EHV-1 at a moi of 5 pfu/cell. Following 1 hour of 
incubation at 37⁰C to allow adhesion of virus (t-1 to t0 in diagram), inocula were removed and 
cells were harvested at t0, t4, t8 and t18 after media was replaced. Expression of EHV-1 genes 
(IE, ICP0, E-VP16 and gB) was analyzed using RT-qPCR. The experiment was performed in 
RNA Isolation  
 RT-qPCR 
EHV-1 
inoculation 
t-1      t0 t4  t8 t18 t-5 
E.Derm Cells  
600 nM 
Thapsigargin  
E.Derm Cells  
2μl DMSO  
Media 
replaced 
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duplicate and repeated on 4 different occasions. The reference gene 18s was used as a normalizer 
and the strategy used to calculate gene expression was as described in section 3.1.5. This analysis 
allowed comparison of gene expression over time with respect to t0.  
 
4.2 Results 
4.2.1 Influence of EHV-1 infection on the UPR 
As shown in Figure 4.1, the expression of the UPR-related genes (HERP, CHOP and 
GRP78) was not increased or decreased in response to EHV-1 infection. 
4.2.2 Influence of the UPR activation on EHV-1 gene expression 
Viral gene expression appeared to follow the pattern observed in untreated cells (compare 
the pattern in Figure 3.5 in the previous chapter with Figure 4.2 below). Transcripts for the IE 
and ICP0 (early) genes could be detected at t4 with a steady increase in gene expression at t8 and 
t18. Expression of the late genes (E-VP16 and gB) at t4 was lower compared to the expression of 
the immediate early and early genes but showed an increased expression at t8 and t18 compared 
to those genes. The levels of expression of each gene under the two conditions (treatment with 
thapsigargin versus untreated) were further compared as a ratio (Figure 4.3) to determine if 
treatment with thapsigargin altered the level of expression of the four indicator genes.  While the 
ratio for all genes was close to 1 at t8 and t18, the ratios were all less than 1 at t4. This suggested 
that UPR activation transiently suppressed expression of EHV-1 genes in the first 4 h after the 
inoculum was removed.   
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4.3 Discussion 
Infection of E.Derm cells with EHV-1 had no effect on UPR gene expression in the 18h 
period of evaluation that started after the inocula were removed and media was replaced. This 
suggests that EHV-1 does not influence UPR gene expression during lytic infection of E.Derm 
cells. 
Activation of the UPR in E.Derm cells before infection with EHV-1 apparently induced a 
reduction in EHV-1 gene expression. This was suggested by the observation that the UPR 
activation suppressed the expression of all four indicator genes at t4; this inhibitory effect was 
not apparent later in infection and viral gene expression was restored at t8 and t18.  
In summary, the fact that lytic EHV-1 infection did not influence the expression of the 
UPR genes and that activation of the UPR suppressed the expression of EHV-1 genes in a 
temporary and reversible manner, these experiments did not provide convincing evidence to 
support the hypothesis that UPR activation plays a role during EHV-1 reactivation from latency.  
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Figure 4.1 Expression of UPR genes during lytic EHV-1 infection in E.Derm cells. Cells 
were harvested at t0, t4, t8 and t18, cellular RNA was isolated, and RT-qPCR was performed. 
Expression of the UPR genes was measured and calculated as fold change compared to time zero 
(t0) (see text above). Dotted lines represent the 2 fold change values considered as biologically 
relevant. Error bars represent standard error, n=7 
 
Figure 4.2 Expression of EHV-1 genes during lytic infection in E.Derm cells treated with 
thapsigargin for 4 h. A) E.Derm cells were treated with 600 nM of thapsigargin prior to 
infection. At t0, t4, t8 and t18 (see diagram), cells were harvested, cellular RNA was isolated, 
and RT-qPCR was performed. Gene expression was calculated as “minus maximum ∆Cq value 
-3 
-2 
-1 
0 
1 
2 
3 
4 8 18 
F
o
ld
 c
h
a
n
g
e
 v
e
r
su
s 
ti
m
e
 z
e
r
o
 
Time after media replacement (hours) 
HERP 
CHOP 
GRP78 
-2 
0 
2 
4 
6 
8 
10 
12 
14 
16 
4 8 18 
 m
in
u
s 
m
a
x
 ∆
C
q
 v
a
lu
e 
time after media replacement (hours) 
IE 
ICP0 
VP16 
gB 
0 
5 
10 
15 
t0 t4 t8 t18 
c
q
 v
a
lu
e
 
Time (hours) 
18s 
A) 
B) 
t t t 
E-VP16 
 96 
 
versus time zero”. B) Expression of 18s over an 18-hour period. RT-qPCR was performed on 
RNA isolated from E.Derm cells at t0, t4, t8 and t18. Average Cq values at each time point are 
shown. Error bars represent standard error, n=4.   
 
  
Figure 4.3 Expression of EHV-1 genes during lytic infection of E.Derm cells after 4 h 
treatment with thapsigargin compared to that in DMSO-treated cells. E.Derm cells were 
either treated with 600 nM of thapsigargin or treated with 2 μl of DMSO as a control and were 
subsequently infected with EHV-1. At t0, t4, t8 and t18 (see diagram), cells were harvested, 
cellular RNA was isolated, and RT-qPCR was performed. Gene expression was calculated as 
“minus maximum ∆Cq value versus time zero” (see section 3.2.5) and ratios of gene expression 
between thapsigargin-treated and control cells determined. The dotted line at value y=1 
represents no change in gene expression. The ratios were calculated from the average of 4 
experiments.  
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5 DETECTION AND ATTEMPTED REACTIVATION OF LATENT 
EHV-1 INFECTION IN EQUINE PERIPHERAL BLOOD CELLS  
The fourth objective of this project was to detect latent EHV-1infection in PBLs obtained 
from horses presumed to be latently infected and to investigate whether stimulation of the UPR 
in these latently-infected PBLs would lead to reactivation of EHV-1 virus. Two approaches were 
chosen to detect latent EHV-1 from PBLs: First, the sensitivity of a nested PCR to detect and 
distinguish latent EHV-1 and EHV-4 was determined and second, co-cultivation of stimulated 
PBLs with cells permissive to EHV-1 infection was assessed. Co-cultivation refers to the culture 
of 2 different cell types in the same medium, and in vitro reactivation of latent EHV-1 by co-
cultivation of PBLs with cells permissive for EHV-1 replication has been described previously 
(Smith, Iqbal et al. 1998). In this chapter, presumed latently infected PBLs were co-cultivated 
with E.Derm cells permissive for EHV-1 replication. If EHV-1 reactivation from latently 
infected PBLs occurred and infectious virus was produced, the E.Derm cells would function as a 
detection system by amplifying the virus. Lytic infection in the E.Derm cells could then be 
detected visually by CPE and presence of viral DNA by qPCR. 
In the previous sections it was established that equine cells respond to cellular stress 
induced by thapsigargin by activating the UPR and that it was possible to detect activation of the 
UPR by using qPCR. It was also established that expression of four EHV-1 genes (IE, ICP0, E-
VP16 and gB) could be detected during lytic infection using qPCR. To achieve the objective of 
this chapter, PBLs isolated from blood samples of horses presumed to be latently infected with 
EHV-1 were treated with different compounds. IL-2 was used as previously described to induce 
reactivation of latent EHV-1 in PBLs in vitro, and thapsigargin was used to induce the UPR.  
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5.1 Materials and methods 
5.1.1 Horses 
Two mares from the WCVM teaching herd were used to collect blood samples and 
isolate PBLs for the initial set-up of co-cultivation experiments. These animals are used for 
teaching purposes in clinical laboratories and classes, and had no recorded history of EHV-1 
infection. Four client-owned horses known to have been exposed to and infected with EHV-1 
during an outbreak of EHM in Saskatoon in 2008 were used as presumed EHV-1 latently 
infected horses. During the outbreak, all four horses tested positive to EHV-1 by PCR (nasal 
swabs) and 2 presented with neurological clinical signs. Specifically, one Quarter Horse gelding 
(17 years of age, horse 1) presented uveitis and mild respiratory signs; one Arabian gelding (22 
years of age, horse 2) presented uveitis and ataxia;  and one Arabian mare (19 years of age, horse 
3) presented ataxia, limb weakness and recumbency during the outbreak. The fourth horses, an 
Arabian/Standardbred mare (11 years of age, horse 4) showed no clinical signs during the 
outbreak. At the time of the study, horse 1, 2 and 4 did not show clinical sequellae and were 
being actively ridden. The Arabian mare presented sporadic limb weakness. All procedures were 
approved by the Animal Research Ethics Board, University Committee on Animal Care and 
Supply (UCACS), University of Saskatchewan, and followed the guidelines of the Canadian 
Council on Animal Care (CCAC).  
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5.1.2 Blood collection, PBLs isolation and cell culture 
Blood collection, isolation and culture of PBLs, and culture of E.Derm cells were 
performed as described in chapter 2. Compounds used to stimulate PBLs and the final 
concentrations used in the experiments are shown in the table below: 
Reagents Final concentration 
DMSO (Dimethyl sulfoxide) 0.4μl or 0.8 μl per ml 
Thapsigargin 750μM in DMSO 300nM or 600nM 
Recombinant human Interleukin 2 (IL-2)* 20IU/ml   
* R&D systems (Minneapolis, USA)  
5.1.3 Virus 
The neuropathogenic field strain of EHV-1 used for establishment of the co-cultivation 
experiments was as described in chapter 3. 
5.1.4 DNA extraction 
DNA (from E.Derm cells and PBLs) was purified using DNeasy kits (Qiagen, Maryland, 
USA) according to manufacturer’s instructions. 
5.1.5 Nested polymerase chain reaction (PCR) 
Conventional (nested) PCR for selective detection of EHV-1 and differentiation from 
EHV-4 was developed previously in Dr. Misra’s laboratory (Table 5.1) (Wagner, Bogdan et al. 
1992). Conventional PCR was performed in a MJ Research PTC-200 peltier thermal cycler (Bio-
Rad Laboratories Inc. Hercules, CA, USA). Nested PCR reactions were performed with the 
following thermal cycler conditions: 94°C for 1 min, followed by 30 cycles of: 4°C for 30 s, 60°C 
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for 30 s, 72°C for 1 min, followed by 10 min at 72°C with a final step at 4°C. Briefly, this nested 
PCR works in 2 steps (Figure 5.1): in the primary reaction, there is amplification with a set of 
primers that recognizes a sequence of the glycoprotein B (gB) gene common to both viruses. The 
product of this primary reaction is a 414 bp “common” product that is used as a template for the 
secondary reaction. In the latter, the same reverse primer as in the primary reaction is used but 2 
different forward primers are used: one specific for EHV-1 gB and one specific for EHV-4 gB. 
The products of this secondary reaction can now be differentiated: a 335bp product is specific for 
EHV-4 and a 129 bp product is specific for EHV-1. Product identification by agarose gel 
electrophoresis was as described in chapter 2.   
To determine the sensitivity of the nested PCR assay, serial 10 fold dilutions of purified 
EHV-1 DNA, ranging from 10 ng/μl to 1 fg/μl, were prepared. Nested PCR was performed on all 
the dilutions and the lowest concentration of DNA that consistently provided positive PCR 
results determined as the limit of detection of the assay. Further, to determine if high 
concentration of cellular (PBLs) DNA would interfere with detection of low viral DNA 
concentrations, decreasing amounts of viral DNA (1 ng, 100 pg, 10 pg, 1 pg) were added to 
increasing amounts of extracted PBLs DNA (250 ng, 500 ng, 1 μg) and nested PCR performed.  
For detection of latent EHV-1 in one presumed latently infected horse (Horse 1 in section 
5.1.1), PBLs were isolated from whole blood and DNA was extracted. Nested PCR was 
performed using 500 ng of input DNA as described above. The horse was tested on 3 separate 
occasions for presence of latent virus.    
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5.1.6 Quantitative real time PCR 
 Quantitative real time (qPCR) targeting the EHV-1 gB gene was performed in a 
Mx3005P QPCR thermal cycler (Stratagene, La Jolla, CA, USA). To determine the presence of 
viral DNA the protocol used was the Quantifast SYBR
®
 green PCR kit protocol, (Qiagen). 
Samples were amplified using the following thermal cycler conditions: 95°C for 5 min, followed 
by 40 cycles of: 95°C for 10 s, 60°C for 30 s, followed by 1 cycle at 95°C for 1 min, 55°C for 30 
s and 95°C for 30 s. The primer sets for transcript amplification were used at a final 
concentration of 12.5 μM.  
5.1.7 Detection of EHV-1 infection in E.Derm cells co-cultivated with isolated PBLs 
Experimental design diagram: 
 
E.Derm cells 
E.Derm  
EHV-1 infected cells 
 
 
 E.Derm                  E.Derm     
  10000pfu                            1pfu 
EHV-1 infected + media 
only 
   E.Derm  
EHV-1 infected+PBLs 
         E.Derm   PBLs 
Mock infected cells 
E.Derm  
Mock infected+media only 
   E.Derm  
Mock infected +PBLs 
E.Derm  PBLs  
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A pilot experiment was designed to study the interaction of EHV-1 infected cultured 
E.Derm cells and PBLs isolated from equine blood samples, and to determine the ability of the 
qPCR assay to detect viral DNA in the total DNA isolated from the co-culture (PBLs+ E.Derm 
DNA). The experiment was performed in duplicate and repeated 3 times (see diagram). E.Derm 
cells (1x10
5
cells/well in 6 well plates) were inoculated with serial 10 fold dilutions of EHV-1 to 
result in a final virus concentration of 10,000, 1,000, 100, 10 and 1 pfu/well, respectively. After a 
1-hour incubation at 37⁰C (5% CO2) for adhesion of virus, inocula were removed. One set of 
wells was maintained in RPMI 1640 medium alone (media only) while the other set had 1x10
6
 
PBLs suspended in RPMI 1640 medium added to the each well. Mock-infected control wells 
were inoculated with media only and cultured with or without the addition of PBLs.   
Wells were visually observed and photographs taken every day for 5 days post-infection 
(DPI). By 5 DPI, cells (both floating cells and attached, E.Derm and PBLs) were harvested as 
follows: supernatant was collected and centrifuged for 5 minutes at 500g and attached cells were 
scraped from the well. DNA was extracted from floating and adherent cells together. The qPCR 
assay targeting the EHV-1 gB gene was performed for all samples.  
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5.1.8 Attempted reactivation of latent EHV-1 and detection by co-cultivation  
Experimental design diagram: 
IL-2 PBL
Thapsigargin PBL
DMSO PBL
Sonicated PBL         
Co-cultivation with 
E.Derm cells
24 hours 5days
Thapsigargin  600nM 4 hours
IL-2 20 IU/ml 24 hours
20h regular medium
24h regular media
DMSO 1μl/ml 4 hours
20h regular medium
Sonicated PBL
Treatment groups
      
Blood samples from horses presumed to be latently infected with EHV-1 (n=3) were 
taken and isolation of PBLs was performed. Considering that 1 in 50,000 PBLs had been 
described to be latently infected with EHV-1 (Smith, Iqbal et al. 1998), 5x10
6 
PBLs/well were 
used as this would ensure presence of at least 100 latently infected PBLs per well. Experiments 
were performed in triplicate and PBLs were treated as follows: the IL-2 PBLs group cells were 
treated with 20 IU/ml of IL-2 in RPMI1640 medium for 24 h; the thapsigargin PBLs group cells 
were treated with 600nM of thapsigargin in RPMI 1640 medium for 4 h and maintained in RPMI 
1640 medium for the following 20 h; the DMSO PBLs group cells served as a control and were 
treated with 1μl/ml of DMSO in RPMI 1640 medium for 4 h and maintained in RPMI 1640 
medium for the following 20 h; and the sonicated PBLs group cells were sonicated 3 times for 7 
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s and maintained in RPMI 1640 medium for 24 h. Sonicated cells were used to control for the 
presence of active viral infection in the samples. With active viral infection, CPE would be 
detected in co-cultivated E.Derm cells because infectious particles (virions) would already be 
present and their production would not depend on cell integrity of the PBLs. Conversely, latent 
virus depends on PBLs integrity to produce infectious particles.  
After 24 h of treatment, PBLs from all groups were co-cultivated with 2x10
5
 E.Derm 
cells/well and maintained in RPMI 1640 medium for 5 days post-exposure (DPE). One group of 
E.Derm cells, cultured in RMPI 1640 medium without addition of PBLs, was added as a control 
and maintained for 5 days. The media was not changed during the 5 day co-cultivation period.   
Photographs were taken every day for 5 days. Five days after the beginning of co-
cultivation, cells were harvested and DNA extracted from both floating and attached cells 
(E.Derm and PBLs). QPCR for detection of EHV-1 DNA was performed on all samples. Three 
different dilutions of the sample DNA were tested (10ng/PCR reaction; 1ng/PCR reaction; 
0.1ng/PCR reaction) to assure that high total DNA concentration was not interfering with viral 
DNA detection. Purified EHV-1 DNA dilutions were used as a positive control with 14.7ng/PCR 
reaction; 1.47ng/PCR reaction and 0.147ng/PCR reaction in each PCR run.   
 
5.2 Results 
5.2.1 Evaluation of a nested PCR to detect viral genomes in PBLs 
A detection limit for the nested PCR of 1 pg of purified viral DNA in up to 500 ng of 
cellular (PBLs) DNA was determined (data not shown). Based on an equine genome size of 
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2.7x10
9 
bp (Wade, Giulotto et al. 2009) and an EHV-1 genome size of 1.5x10
5
 bp (Telford, 
Watson et al. 1992), the necessary frequency of latent infection to ensure presence of 1 pg of 
viral DNA in 500 ng of cellular DNA could be calculated. It was determined that 1pg of viral 
DNA in 500 ng of PBLs DNA was equivalent to 1 viral genome in 27 PBLs, i.e. 1 in 27 PBLs 
would need to be latently infected in order to make the nested PCR a useful and reliable tool for 
detection of latent EHV-1 infection. In comparison, the frequency of latent infection in equine 
PBLs has been described as 1 in 50,000 cells (Smith, Iqbal et al. 1998). Blood samples from one 
presumed latently infected horse were tested with this PCR technique 3 times and it tested 
positive to EHV-1 on only one occasion. The sensitivity of the assay in relation to the frequency 
of the latent virus therefore represents a limitation for the use of this detection technique.  
5.2.2 Detection of EHV-1 infection in E.Derm cells co-cultivated with isolated PBLs 
Figure 5.2 shows photographs of the co-cultivated wells of the pilot experiment on day 1 
and day 4. Starting from the left, the first column shows images of wells inoculated with the 
lowest dilution of virus (1x10
5 
pfu/well). In wells cultured with media alone, presence of CPE 
was clearly detected over large areas on 1D PI. By 4 DPI, no E.Derm cells remained attached to 
the wells and clumps formed by detached cells were visible. In wells cultured with PBLs, CPE 
could be detected but visualization was not as clear as in wells without PBLs. By 4 DPI, only 
few E.Derm cells remained attached to the well and large clumps of detached E.Derm cells 
aggregated with PBLs were visible.  
The second column in Figure 5.2 represents images of wells inoculated with a media 
containing diluted virus (1x10
3 
pfu/well). In wells cultured with media alone, presence of CPE 
was detected on 1 DPI in certain areas across the well as plaques and rounded, refringent cells 
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were visible surrounding these plaques. By 4 DPI, almost all E.Derm cells looked rounded and 
more refringent but many of those cells were still attached to the well. In wells cultured with 
PBLs, presence of CPE was detected on 1 DPI in isolated E.Derm cells but detection of CPE on 
4 DPI was difficult. There were individual cells with CPE characteristics and areas with detached 
E.Derm cells. However, there was no clear visualization of plaques or CPE.  
The third column in Figure 5.2 represents images of wells inoculated with the lowest 
concentration of virus (1
 
pfu/well) used for this experiment. In wells cultured with and without 
PBLs, no CPE were detected on 1 DPI. In wells cultured with media alone, 33% of the wells 
presented CPE on 4 DPI, while in wells cultured with PBLs, there were no detectable CPE. In 
wells without distinct CPE, E.Derm cells with PBLs looked different from those without PBLs 
on 4 DPI. 
In the last column in Figure 5.2, images of mock infected E.Derm cells are shown. In 
wells cultured with media alone, cells had the appearance of normal dermal cells on day 1 and 4. 
In wells cultured with PBLs, the high number of PBLs hampered correct visualization of the 
E.Derm cells on day 1. On day 4, E.Derm cells cultured with PBLs showed different morphology 
compared to those cultured without PBLs. This was consistent with the findings of infected cells 
in wells without distinct CPE (see above). Therefore, integrity of E.Derm cells was compromised 
after 4 days of co-cultivation with PBLs. Visualization of CPE in wells containing PBLs was 
difficult because of the high total number of cells per well. In wells with a higher concentration 
of virus, the presence of PBLs hindered the detection of CPE on 4 DPI but it did not impede 
detection of CPE entirely.  
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The results of CPE detection were corroborated by qPCR. All wells that had CPE 
detected visually tested positive for presence of viral DNA by qPCR (Figure 5.3). Wells in which 
CPE were not detected visually (wells inoculated with the highest
 
dilution of virus and cultured 
with PBLs, mock infected E.Derm cells cultured with PBLs and mock infected E.Derm cells 
cultured in  media alone) tested negative for viral DNA presence by qPCR.  
5.2.3 Attempted reactivation of latent EHV-1 and detection by co-cultivation 
E.Derm cells and treated PBLs from horses presumed to be latently infected were co-
cultivated for 5 DPE. During the co-cultivation period, CPE could not be detected in any group 
(Figure 5.4). Co-cultivation of E.Derm cells with PBLs for more than 3 DPE induced changes in 
morphology in the E.Derm cells. Normal E.Derm are adherent large, elongated, spindle shaped 
cells (Leeson, Leeson et al. 1985) while the co-cultivated E.Derm cells looked shorter, rounded 
or oval shape, detached from the well and in some cases more refringent. A reduction in the 
number of both PBLs and E.Derm cell types over time was appreciated visually but not 
confirmed by cell counting. For 3 treatment groups (IL-2, Thapsigargin and DMSO treated 
PBLs), there was a clear reduction in cell number and by 5 DPE, it was extremely difficult to 
identify E.Derm cells in each well. The co-cultivated wells from the sonicated PBLs group were 
the only wells not showing morphological changes in the E.Derm cells or visible reduction in the 
number of cells by day 5 of co-cultivation. Viral DNA was not detected by qPCR in DNA 
samples isolated from any of the wells (data not shown).  
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5.3 Discussion 
Conventional nested PCR does not appear useful for reliable detection of the latent EHV-
1 genome if, as estimated in the published literature, only one latent viral genome per 50,000 
PBLs is present. 
From the pilot experiment I concluded that the presence of PBLs in the co-cultivated 
wells interfered with the visualization of CPE only at the highest dilution of the virus. Wells 
where CPE was present tested positive by PCR targeting EHV-1 gB.  
The attempted reactivation of latent EHV-1 from PBLs and detection by co-cultivation 
was not achieved because either the reactivation stimulus was not the correct one or the virus 
was not present in the examined samples. 
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Table 5.1 Primers for detecting and differentiating EHV-1 and EHV-4 DNA. Four different 
primers targeting EHV gB are used in this nested PCR. EHV1P1 is the common forward primer 
and EHV1P2 is the common reverse primer. The product obtained from the amplification with 
these primers is a 414 bp product “common” to both viruses. This product is then used as a 
template for the secondary reaction. In the secondary reaction, EHV1-2P1 is used as the forward 
primer specific for EHV-1 detection, EHV4-2P2 is used as the forward primer specific for EHV-
4 detection and EHV1P2 is used as the reverse primer common to both sequences.  
 
 
 
 Sequence 
Template 
strand 
Length (in bp) 
Tm     
(in ºC) 
GC% 
EHV1P1  common to both 
viruses   
Forward primer    
ATGTCCWCTKGTTGCCG (w=a/t, 
k=t/g)  
Plus 17 47-49 52-58 
EHV1-2P1 EHV-1 specific  
Forward primer    
TACTCCCACTTCCATGTCAACG Plus 22 55 50 
EHV4-2P2  EHV-4 specific 
 Forward primer   
CGTGTTCTCGCTTCTATACACC Plus 22 55 50 
EHV1P2  common to both 
viruses  
Reverse primer   
TGTAAAAGTCTCCATCC  Minus 17 42 41 
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EHV-4
EHV-1
EHV-4
EHV-1
EHV-4
EHV-1
EHV-4
EHV-1
Primary 
reaction
Common
Product
414 bp
Secondary 
reaction
Products
335 bp
129 bp
 
Figure 5.1 Nested PCR for detecting EHV-1 and EHV-4. In the primary reaction, the light 
grey arrows represent primers common to EHV-1 and EHV-4. The product from the primary 
reaction is a 414 bp product “common” to EHV-1 and EHV-4. In the secondary reaction, the 
green arrow represents the forward primer specific for EHV-4 glycoprotein B and the black 
arrow represents the forward primer specific for EHV-1. The products of the secondary reaction 
are specific for each virus. For EHV-4, it is a 335 bp product and for EHV-1 it is a 129 bp 
product.    
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Figure 5.2 Co-cultivation of EHV-1 infected E. Derm cells and equine PBLs. Photographs of 
representative co-cultivated wells were taken on 1 DPI and 4 DPI. CPE are detectable as 
rounded, detached and refringent cells (white arrow heads). Viral infection produces detachment 
of cells from the well with plaques appearing as clear areas between infected cells (black 
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arrows). On 4 DPI, wells containing high viral concentration showed clumps of cells (white 
arrows). Presence of PBLs made visual detection of CPE difficult. 10X magnification. 
 
 
Figure 5.3 In vitro detection of EHV-1 CPE 5 DPI. E.Derm cells (1x10
5
 cells/well) were 
inoculated with 10 fold dilutions of EHV-1. Six wells per viral dilution were co-cultivated with 
PBLs and six without PBLs. The number of wells showing CPE on 5 DPI is plotted.   
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Figure 5.4 Co-cultivation of E.Derm cells and presumed latently EHV-1 infected equine 
PBLs. Photographs of representative co-cultivated wells were taken every day for 5 days. After 
day 3 of co-cultivation with IL-2 PBLs, thapsigargin PBLs and DMSO PBLs, E.Derm cells 
showed different morphology than E.Derm cells co-cultivated with sonicated PBLs. Distinct 
CPE indicative of viral reactivation were not observed in any of the wells. 10X magnification. 
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6 DISCUSSION 
EHV-1 appears to be very different from the other, more extensively studied, members of 
the Alphaherpesvirinae such as HSV-1 and VZV. EHV-1 has been described to establish latency 
in PBLs as well as sensory ganglia, whereas HSV-1 and VZV are latent in sensory neurons 
alone. EHV-1 may therefore allow the study of stress stimuli and signalling pathways that 
influence latency of an alphaherpesvirus in its natural host without having to sacrifice the host to 
remove its sensory ganglia. The collection of relatively large amounts of blood from latently 
infected horses is simple and feasible.  
The UPR is a sensor of the stress level in the cell. Physiological activation of the UPR in 
normal cells is not detrimental for the cells and increases the cell protein folding capacity. When 
the stressful stimulus that induces the UPR is prolonged in time and of such intensity that it 
cannot be mitigated by the adaptive phase of the UPR, the cell undergoes apoptosis. It has been 
shown that during early lytic HSV-1 infection, the virus can modulate the activation of the UPR 
to avoid the detrimental aspects, while taking advantage of the positive aspects of UPR 
activation (Burnett, Audas et al. 2012). It has been proposed that ER stress related factors can be 
involved during HSV-1 latency establishment and reactivation (Figure 1.4). As there is still no 
proposed molecular model for establishment of EHV-1 latency and reactivation, I wanted to test 
the hypothesis that induction of ER stress with the consequent UPR activation in latently EHV-1 
infected equine peripheral blood leukocytes (PBLs) could be a sufficient stimulus to trigger 
reactivation from latency.  
To test this hypothesis, I first needed to be certain that the UPR could be consistently 
activated in equine cells and that the activation was measurable. This work is described in 
chapter 2. As PBLs are highly demanding cells to culture and do not replicate under natural 
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culture conditions, the E.Derm cell line was selected for preliminary work in the laboratory. I 
determined that treatment of E.Derm cells for 4 h with 600nM of thapsigargin (a drug that has 
been shown to induce the UPR in a number of cell lines of different origins, but has been not 
tested in the E.Derm cell line) induced the expression of UPR related genes (GRP78, HERP and 
CHOP) as measured by RT-qPCR. The GRP78 and the XBP1s genes primer set were designed 
for equine cells; however, while the identity of the amplification product for both XBP1s primer 
sets was validated by sequencing, XBP1s expression was not consistently induced after 
thapsigargin treatment in E.Derm cells and hence, this primer set was not included in the 
subsequent experiments with this cell line. The remaining primer sets used to measure the gene 
expression of HERP and CHOP after UPR activation had been tested in canine and human cells 
and were validated to amplify the correct target when used in equine cells. As described in 
chapter 2, efficiency of amplification of the primers for the reference gene 18s, for GRP78 gene 
and XBP1s gene was adequate but the efficiency of amplification for CHOP and HERP was not 
adequate. Efficiency values of greater than 150% for those primers could indicate that more than 
one product were amplified in the reaction. The dissociation curves for CHOP and HERP 
suggested that mispriming or primer-dimer artifacts may have occurred during the PCR 
amplification. However, the identity of the amplification products for both primer sets was 
established after thapsigargin treatment of the cells and the increase in the expression of both 
CHOP and HERP transcripts was consistently determined. I was also able to induce and measure 
the UPR gene expression in PBLs isolated from horse blood samples following the same 
protocol of UPR activation as for E.Derm cells. I therefore established that the UPR could be 
activated and measured in both cell types (E.Derm and PBLs) but the activation profile in both 
cell types differed to some extent: expression of XBP1s was induced in PBLs but it was not 
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induced in E.Derm cells after thapsigargin treatment; in contrast, expression of HERP was 
induced in E.Derm cells but it was not induced in PBLs after thapsigargin treatment. This 
difference in gene expression between the E.Derm and PBLs was not expected and may be a 
consequence of the different nature of the cells. Dermal cells are cells with higher metabolic 
activity compared to PBLs, and it is possible that some cellular pathways related to the UPR 
present different activation profiles in these 2 cell types. Unfortunately, the published literature 
lacks evidence to support a potential specific cause of the observed difference in UPR gene 
expression in my experiments.    
In chapter 3, I established that our neuropathogenic EHV-1 virus stock was able induce 
lytic infection in the E.Derm cells at a low moi (0.01 pfu/cell) and that I was able to detect that 
lytic infection. CPE due to EHV-1 could be detected 24 HPI in E.Derm cells (Figure 3.1) and the 
growth of the virus in E.Derm cells increased exponentially over 36 h as described in the single 
step growth curve (Figure 3.2). The growth of EHV-1 observed in this experiment was similar to 
what has been published previously for EHV-1 and consistent with the growth characteristics of 
other alphaherpesviruses.  
Also in chapter 3, the expression of EHV-1 genes was successfully detected by RT-qPCR 
over an 18 h period (Figure 3.5A). The expression of the IE and E genes at t4 was comparatively 
higher than the expression of the L genes. The expression of all the gene classes was increased at 
t8 and t18. The increased expression of all gene classes simultaneously can be explained because 
in culture, we can find infected cells that are at the first stages of infection, expressing the IE 
gene, and other cells that are in a later stage of infection, expressing the E or the L genes, in the 
same well. The objective of this experiment was to determine the ability to detect viral 
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transcripts in infected cells at different time points by qPCR, not to describe the temporal 
expression of the viral genes.  
In chapter 4, I explored the potential interaction of EHV-1 and the UPR during lytic 
infection to investigate if one might influence the other. Two experimental designs were 
performed. In the first experiment, I evaluated the influence of EHV-1 infection on UPR gene 
expression. To that end, E.Derm cells were infected with EHV-1 at a moi of 5pfu/cell, harvested 
at different time points over an 18 h period and RT-qPCR was performed to measure the 
expression of the UPR genes (Figure 4.1). The expression of the 3 UPR genes (GRP78, CHOP 
and HERP) was not altered at any of the investigated time points after EHV-1 infection. I 
concluded that lytic EHV-1 infection does not influence the expression of CHOP, HERP or 
GRP78 genes, partially refuting the hypothesis that EHV-1 reactivation from latency relies on 
the activation of the UPR. 
 In the second experiment in chapter 4, I evaluated the possible influence of an activated 
UPR on the EHV-1 gene expression. E.Derm cells were first treated for 4 h with thapsigargin or 
DMSO, and were then inoculated with EHV-1 at a moi of 5pfu/cell, harvested at different time 
points in an 18 h period and RT-qPCR was performed to measure the expression of the EHV-1 
genes. The expression of all measured EHV-1 genes in UPR activated infected cells at different 
time points resembled the expression of EHV-1 genes in untreated infected cells (Figure 3.5 A 
and Figure 4.2 A). The levels of expression of each gene under the two conditions were 
compared as a ratio (Figure 4.3) and while the ratio for all genes was close to 1 at t8 and t18, the 
ratios were all less than 1 at t4. This suggested that although the UPR suppressed the expression 
of all three indicator genes at t4, this inhibitory effect was not apparent later in infection. 
Activation of the UPR could therefore temporarily influence viral gene expression or viral 
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protein expression, as immediate early and early proteins are required for expression of late viral 
proteins. Nonetheless, it was a temporary and reversible effect as gene expression was restored at 
t8 and t18.         
In chapter 5, I attempted reactivation of latent EHV-1 from PBLs in vitro. To detect 
latent EHV-1 infection in PBLs, 2 different approaches were attempted. The first approach 
involved the use of a nested PCR, described in chapter 5. A detection limit of 1 pg of purified 
viral DNA in 500 ng total cellular DNA was determined. This corresponded to a required 
frequency of latent infection of approximately 1 viral genome per 27 cells. It has been described 
in the literature that the frequency of latently infected PBLs is 1 in 50,000 cells (Smith, Iqbal et 
al. 1998). This suggested that the PCR detection technique would not be sensitive enough to 
detect latent EHV-1 in PBLs and may explain why blood samples from a presumed latently 
infected horse yielded inconsistent results by the PCR technique.  
The second approach involved the use of co-cultivation as the detection technique to 
identify reactivating virus when EHV-1 latently infected PBLs were treated with chemicals to 
induced viral reactivation. With co-cultivation, E.Derm cells would amplify infectious 
reactivated virus originating from the PBLs and allow CPE detection and detection of EHV-1 
gene expression by PCR. The rationale for using co-cultivation was that over a million PBLs 
could be seeded onto permissive E.Derm cells and reactivation in a single PBLs would be 
amplified several thousand fold by replication in E.Derm cells. The reported low frequency of 
latent EHV-1 infection in PBLs (as mentioned above) would therefore, no longer represent a 
limitation for virus detection.  
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A pilot experiment was designed to evaluate the interaction of the amplifying system 
cells (E.Derm), the PBLs and the virus (EHV-1) in the co-culture environment, and to determine 
the efficiency of detection of lytic EHV-1 infection in this system. Lytic EHV-1 infection was 
detected by visualization of CPE and by qPCR to detect viral DNA. E.Derm cells were 
inoculated with serial dilutions of EHV-1 and incubated in the presence or absence of PBLs. 
From this pilot experiment, I concluded that the presence of PBLs in the co-cultivation wells 
interfered with the visualization of CPE and that, after 4 days of co-cultivation, the presence of 
the PBLs compromised the integrity of the E.Derm cells. I was also able to confirm that by co-
cultivation of PBLs and E.Derm cells, I could consistently detect viral presence as low as 
10pfu/well by visualization and qPCR. I was not able to consistently detect viral infection when 
the wells were inoculated with the viral dilution corresponding to 1 pfu/well. The serial dilutions 
from the stock virus were performed and the highest dilution tested should have contained 1 pfu 
per total volume. Considering that the inoculum was an aliquot of the total dilution volume, there 
is a chance that the 1 viral pfu was actually not introduced to the well. Usually, it would be 
expected that viral infection occurred if 1 pfu is present in the well. 
 Once the efficiency of co-cultivation for detection of lytic EHV-1infection was 
determined, I attempted in vitro reactivation of EHV-1 from latently infected PBLs by 
thapsigargin-induced activation of the UPR. IL-2 was used as a positive control stimulus to 
induce in vitro reactivation of EHV-1 from latently infected PBLs, as described by others (Smith, 
Iqbal et al. 1998). Blood samples from 3 different horses that were involved in an outbreak of 
EHM in the Saskatoon area in 2008 were used; 2 of those horses had clinical signs of EHV-1 
infection when the outbreak occurred and all 3 horses had nasal swabs that tested positive by 
PCR to EHV-1 at the time of the outbreak. The PBLs were first incubated with thapsigargin or 
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IL-2 for the specified times (Figure 5.4), while control PBLs were incubated with DMSO or 
were sonicated and incubated in regular medium (as a control for the presence of active viral 
infection in the samples). Twenty four h after the beginning of the treatment, PBLs were co-
cultivated with E.Derm cells for 5 days and qPCR performed on isolated DNA on day 5. During 
the co-cultivation period, CPE could not be detected in any group. There was also no detection of 
viral DNA by qPCR in any of the DNA samples isolated on day 5 of co-cultivation.  
From these experiments, I concluded that the presence of the PBLs in the co-cultivation 
wells seemed to compromise the integrity of the E.Derm cells after 4 days of co-cultivation. 
Comparing the pilot experiment with the final experiments: the same cell types (E.Derm cells 
and PBLs) were co-cultivated using the same medium (RPMI 1640), for the same period of time, 
under the same incubation conditions. In the pilot experiment, cells were not treated with 
chemicals and the changes in the E.Derm cell morphology seemed less severe compared to the 
treated co-cultivated wells. The sonicated cells were not treated with any chemicals and those co-
cultivation wells appeared to show less cellular damage compared to the treated co-cultivated 
wells. Treatment with IL-2, thapsigargin and DMSO may have had a detrimental effect on the 
PBLs cells that later induced a detrimental effect on the E.Derm cells. PBLs media after 
treatment were washed and replaced with fresh media before co-cultivation with E.Derm cells. 
However, compounds may still have been present and directly affect the E.Derm cells in the 
well. Nevertheless, if viral reactivation had occurred in any of the treated wells it would have 
been expected to correlate with CPE detection at any time point of the co-cultivation period and 
detection of viral DNA by qPCR.   
Detection of latent EHV-1 genomes from PBLs of horses presumed to be latently infected 
was not achieved by using either PCR or co-cultivation. Reactivation of latent EHV-1 from 
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PBLs was not achieved because either the reactivation stimulus was not the correct one or virus 
was not present in the examined samples. As latent EHV-1 infection could not be reliably 
detected in PBLs, I could not draw definitive conclusions about the potential effect of 
thapsigargin and of UPR activation on latently EHV-1 infected cells. I was not able to reproduce 
the results obtained by Smith and others as the use of IL-2 did not result in viral reactivation 
from presumed latently EHV-1 infected PBLs in vitro.  
Regarding the reasons why I was not able to detect latent EHV-1 in PBLs from blood 
samples of horses presumed to be latently infected with the virus, I propose the following 
hypotheses: 
1)  All the blood samples used in this project were from horses. Most of the literature 
involving EHV-1 latency and reactivation in PBLs has been described in Welsh 
Mountain ponies (Edington, Bridges et al. 1985; Gibson, Slater et al. 1992; Welch, 
Bridges et al. 1992; Slater, Borchers et al. 1994; Baxi, Efstathiou et al. 1995). There is 
published evidence that inflammatory processes are different in horses and ponies. 
Studies investigating the wound healing process revealed differences in leukocyte 
function and cytokine profiles of the local inflammatory response between horses and 
ponies (Wilmink, Stolk et al. 1999; Van Den Boom, Wilmink et al. 2002; Wilmink, 
Veenman et al. 2003). There is a lack of published evidence regarding the differences in 
the inflammatory response between horses and ponies; however, it is possible that 
interpretations made based on information gathered about EHV-1 latency and 
reactivation from ponies is not applicable to EHV-1 latency and reactivation in horses.  
2) The attempts to induce EHV-1 reactivation by chemical induction in my project were 
performed in vitro using isolated PBLs. Identification of the specific cells harbouring 
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latent infection, before induction of reactivation in vivo, may be needed to determine if 
latent infection does occur in circulating PBLs. In the first reports of EHV-1 reactivation 
by co-cultivation of PBLs, the reactivation was induced in ponies in vivo with drugs 
(Edington, Bridges et al. 1985; Welch, Bridges et al. 1992). Blood samples were then 
collected and co-cultivated. Induction of viral reactivation in vivo can mislead the 
interpretation of the specific cell type harbouring the latent virus. Upon reactivation, the 
specific tissues latently infected with EHV-1 can amplify the viral infection to 
surrounding tissues from where the circulating PBLs can be productively infected with 
the virus. Hence, it is possible that the co-cultivation described in some of those reports is 
due to at least 1 productively infected PBLs in the blood sample. Interestingly, in the 
most recent report describing EHV-1 reactivation in latently infected horses in vivo 
(Pusterla, Hussey et al. 2010), the authors were able to determine reactivation by transient 
molecular detection of EHV-1 but they were not able to isolate the virus by co-
cultivation. In a study published by Allen (Allen 2006), the author discussed the 
difference between “real” latency versus persistent infection in PBLs, as true latency of 
the viral genome was only detected in samples from mandibular lymph nodes but not in 
circulating leukocytes.  
3) There is currently, to my knowledge, only one published report describing in vitro 
reactivation of EHV-1 from latently infected PBLs (Smith, Iqbal et al. 1998). In this 
study, the researchers used blood samples collected post-mortem from latently infected 
ponies (previously experimentally infected with EHV-1) and blood samples from abattoir 
horses of unknown EHV-1 infectious state. The concern that arises about that publication 
is that the authors did not specify how they assessed the infectious status of the animals 
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from which the samples were collected. If any of those animals had experienced a recent 
viral reactivation, the authors had no means to determine the difference in the origin of 
the active viral infection observed in culture. Whether the lytic infection detected in cell 
culture originated from reactivation in vitro or from reactivation in vivo was not 
conclusively proven. I attempted to reproduce the IL-2 induced in vitro reactivation of 
EHV-1 using PBLs collected from horses presumed to be latently infected as described 
by these authors and I was not able to obtain viral reactivation.  
While the original hypothesis of this thesis was that activation of a cellular stress 
response, the UPR (shown to be related to molecular events in other viral infections), could 
induce reactivation of EHV-1 from latently infected PBLs, a broader discussion emerged from 
my results and the review of the literature related to EHV-1 latency.  
There is still an enormous lack of information regarding the molecular aspects of EHV-1 
latency, and most of the conclusions arrived at in the past were extrapolated from evidence 
obtained from HSV-1 models. Even though EHV-1 and HSV-1 are both members of the 
alphaherpesvirus subfamily, there is a clear difference in the proposed viral behaviour. The 
question arises then, why would an alphaherpesvirus like EHV-1 establish latency in leukocytes? 
Other members of this subfamily, like BHV-1 and PRV, have been proposed to establish latency 
in mammalian lymphoid tissue although this has not been conclusively proven. Both viruses 
have been shown to be present in the tonsils but latency in PBLs has been not reported (Balasch, 
Pujols et al. 1998; Winkler, Doster et al. 2000). EHV-1 has been suggested to establish latency in 
lymphoid tissues (Welch, Bridges et al. 1992; Edington, Welch et al. 1994) such as 
retropharyngeal, submandibular, bronchial and tonsillar lymph nodes. What is the biological 
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implication for this switch in the site to establish latency for these viruses? It is worth 
considering that EHV-1 establishes latency in lymphoid tissues related to the respiratory tract, as 
do BoHV-1 and PRV. In this location, the virus could gain an advantage by reactivation in a 
tissue related to a mucosa from where it can increase the transmission. Evolutionarily, does this 
feature confer any advantage for EHV-1 over other alphaherpesviruses?  
The presence of viral genome in PBLs has been detected in several studies which should 
not be disregarded. Is it possible that detection of EHV-1 genome in a very small proportion of 
PBLs during latent infection is the result of a non-productive rather than latent infection in those 
cells? The mere presence of the EHV-1 viral genome in PBLs cannot be regarded as proof of 
latent infection. In the study conducted by Pusterla and collaborators, the authors characterized 
the viral loads, strain and state of EHV-1 using qPCR in horses following natural exposure at a 
racetrack. They tested nasopharyngeal secretions (NPS) and whole blood samples of more than 
70 adult horses for three weeks after the confirmation of a neurological case of EHV-1 in a 
racetrack (Pusterla, Wilson et al. 2009). They assigned three possibilities for viral state (table 
6.1) based on the molecular expression of LAT in cDNA and the expression of gB in genomic 
DNA (gDNA) or cDNA as: Lytic, Non-replicating or Latent. Five horses showed expression of 
LAT transcripts in blood samples. Four of those animals simultaneously tested positive in NPS 
for expression of gB in gDNA and cDNA, corresponding to the lytic viral state. Only one of the 
horses tested positive for LAT expression in the blood sample without expression of the gB gene 
in NPS, therefore corresponding to the latent viral state. In addition, only one horse tested 
positive for gB from gDNA detection in the blood sample without expression of LAT, 
corresponding to the non-replicative viral state. The authors suggested that categorization of 
distinct  viral states might be regarded as simplistic, since “during an ongoing EHV-1 infection, 
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the viral state rarely satisfies the all or none rule, but rather progressively transitions from one 
state to the next” (Pusterla, Wilson et al. 2009). They also commented on the possibility that 
detection of gB DNA without expression of gB RNA could account for abortive EHV-1 infection 
or early reactivation from latency. If latency is defined as the presence in a cell of the viral 
genome, without detectable expression of viral genes (with the exception of the LAT transcripts) 
and without detectable virus production together with the ability to resume viral replication when 
exposed to a reactivating stimulus (Preston 2008), the detection of only one of those 
characteristics appears to be insufficient to determine latency.  
 Table 6.1 Determination of viral state corresponding with the molecular expression of the 
selected target genes in nucleic acids. Adapted from Pusterla 2009. 
 
 
 
 
 
As commented previously, Allen and colleagues also presented evidence that challenged 
the theory of PBLs as site of latency. In a study where samples from mandibular lymph nodes 
(MLN) and PBLs were collected in vivo, 18 out of 24 animals expected to be latently infected 
tested positive for EHV-1 DNA in MLN by a sequence-capture nested PCR. Those 24 horses had 
been infected with EHV-1 four to five years previous to this experiment. All the animals that 
tested positive in MLN tested negative in PBLs. The authors posed the question whether the 
detection of viral DNA in PBLs in previous investigations “represented a true latent state or 
active persistent infection by the virus” (Allen 2006).  
Target gene Nucleic acid Viral state                                      
Lytic      Non-replicating Latent 
gB 
 
LAT 
gDNA 
cDNA 
cDNA 
Yes             Yes                  Yes 
Yes             No                   No 
No              No                    Yes 
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After reviewing the published literature regarding EHV-1 latency and taking into account 
the results of my investigation where I was not able to detect latent EHV-1 in PBLs from horses 
presumed to be latently infected with EHV-1, I suggest that the concept of EHV-1 establishing 
latency in PBLs should be revised. The evidence suggests that future work involving EHV-1 
sites of latency should focus on lymphoid tissue related to the respiratory tract.     
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